Clinical Study Report  
16.1 Study Information 
1. PROTOCOL AND AMENDME NTS
The final global protocol for study TO- TAS-102-203 (Original version, dated 14 June 2016) is 
provided in this appendix.  This original protocol was not amended at any time during or after 
the study. 
$3KDVH6WXG\ZLWK6DIHW\/HD GLQ(YDOXDWLQJ7$63OXV1L YROXPDELQ3DWLHQWVZLWK
0LFURVDWHOOLWH6WDEOH5HIUDFWRU \0HWDVWDWLF&RORUHFWDO&DQFHU 
7$6
3URWRFRO1XPEHU727$6
,1'1XPEHU 
)LQDO-XQH
7DLKR2QFRORJ\,QF
&DUQHJLH&HQWHU6XLWH
3ULQFHWRQ1-86$
6SRQVRU&RQWDFW
0'

7DLKR2QFRORJ\,QF
7HOHSKRQH 
)DFVLPLOH 

6SRQVRUÂ¶V0HGLFDO0RQLWRU
0'0%$

5RFNPRQW&LUFOH
%RXOGHU&2
86$
7HOHSKRQH 
)DFVLPLOH 

7KLVFOLQLFDOVWXG\ZLOOEHFRQGXFWHGLQDFFRUGDQFHZLWK,QWHUQ DWLRQDO&RXQFLOIRU+DUPRQLVDWLRQ*RRG
&OLQLFDO3UDFWLFH*&3*XLGHOLQHV
&21),'(17,$/[COMPANY_003]CCI
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
TAS-102 
Protocol No. TO -TAS-102-203 Metastatic Colorectal Cancer  
TO-TAS-102-203 Version 1.0 14 June 2016 Page 2 of 80 1. SYNOPSIS
Name [CONTACT_790]/Company:  Taiho Oncology, Inc.  
Name [CONTACT_791]:  TAS-102 and nivolumab  
Name [CONTACT_19138]:  TAS-102: trifluridine (FTD) and tipi[INVESTIGATOR_13071] (TPI) ; 
Nivolumab: nivolumab 
Title of Study:  
A Phase 2 Study with Safety Lead -in, Evaluating TAS -102 Plus Nivolumab in Patients with 
Microsatellite -Stable Refractory Metastatic Colorectal Cancer 
Protocol Number:  TO-TAS-102-203 
Phase of Development:  2 
Indication:  Refractory metastatic colorectal cancer 
Background/Rationale:  â€¢TAS-102 is an oral combination of 1M trifluridine ( FTD) and 0.5M tipi[INVESTIGATOR_19073] (TPI).
â€¢The primary mechanism of action of FTD, an antineoplastic thymidine -based
nucleoside analog, is incorporated  into DNA via phosphorylation,  resulting in a
different cytotoxic mechanism from  5-fluorouracil  and 2â€™-deoxy-5-
fluorouridine  (uracil-based thymidylate synthase inhibitors).
â€¢TAS-102 has been shown to significantly improve overall survival (OS) in
patients with metastatic colorectal cancer (mCRC) who have been previously
treated with, or are not candidates for fluoropyrimidine -, oxaliplatin -, and
irinotecan -based chemotherapy, an anti -vascular endotheli al growth factor
(VEGF) biological therapy, and an anti -epi[INVESTIGATOR_19074] r
(EGFR) therapy .9
â€¢Treatme
nt with pembrolizumab ( an anti-programmed cell death-1 [PD-1]
antibody similar to nivolumab) , shows activity in patients with  mCRC.
However, in patients with microsatellite instability (MSI) tumors, anti-PD-1
activity was much higher than in patients with microsatellite -stable (MSS)
tumors. The median progression- free survival ( PFS) and OS were not
reached in the MSI-high mCRC patient. In contrast, the median PFS and
OS were  2.2 months and 5.0  months, respectively, in the coh ort with MSS
mCRC patients (hazards ratio for PF S was 0.10 [ P < .001], and hazards ratio for
OS was 0.22 [ P = .05]). Moreover, the overall response rate (ORR) for mCR C
patients with MSI -high and MSS was 40% and 0%, respectively.10
â€¢In a pre
clinical study, the tumor growth inhibitory activity of TAS -[ADDRESS_17944] mouse  colorectal cancer cell (CMT -93/MSS
cell line). The results of this preclinical study showed that synergistic effects
occurred when using TAS -102 with anti -mouse PD -1 antibody in  mouse
colorectal cancer cells.
â€¢The proposed mechanism for the observed additive or synergistic effect is anincrease in tumor immunogenicity after treatment with TAS -102, leading to a
better tumor response to anti -PD-1 antibody therapy. Increased tumor
immunogenicity may be triggered by [CONTACT_19095] -102 DNA incorporation. This
Phase 2 study will examine this hypothesis.
7$6
3URWRFRO1R727$6 0HWDVWDWLF&RORUHFWDO&DQFHU
727$69HUVLRQ-XQH  3DJH RI6WXG\2EMHFWLYHV 7RHYDOXDWHWKHIROORZLQJREMHFWLYHVLQSDWLHQWVZLWKP&5&UHFH LYLQJ7$6LQ
FRPELQDWLRQZLWKQLYROXPDE
3ULPDU\2EMHFWLYH
x7RHVWLPDWHWKHLPPXQHUHODWHGR YHUDOOUHVSRQVHUDWHLU255RI 7$6DQG
QLYROXPDEFRPELQDWLRQWKHUDS\LQP&5&SDWLHQWV
6HFRQGDU\2 EMHFWLYHV
x7RFRQILUPWKHUHFRPPHQGHG3KDVHGRVHIRUWKHFRPELQDWLRQWKH UDS\RI
7$6DQGQLYROXPDE
x7RDVVHVVWKHVDIHW\RI7$6DQGQLYROXPDEJLYHQDVFRPELQDW LRQWKHUDS\
x7RHVWLPDWHWKH255XVLQJ5HVSRQVH(YDOXDWLRQ&ULWHULDLQ6ROLG 7XPRUV
5(&,67YHUVLRQ
x7RHVWLPDWHWKH3)6EDVHGRQLPPXQHUHODWHGUHVSRQVHFULWHULD LU5&DQG
5(&,67
x7RHVWLPDWHWKHGLVHDVHFRQWURO UDWH'&5XVLQJLU5&DQG5(&,6 7
x7RHVWLPDWHWKH26
6WXG\'HVLJQ 7KLVLVDPXOWLFHQWHUVLQJOHDUP VDIHW\OHDGLQ3KDVHVWXG \XVLQJ6LPRQÂ¶V
VWDJHGHVLJQHYDOXDWLQJWKHVDIHW\DQGHIILFDF\RI7$6SO XVQLYROXPDELQ
SDWLHQWVZLWK066UHIUDFWRU\P&5&
3DWLHQWVZLOOXQGHUJRVFUHHQLQJWRDVVXUHHOLJLELOLW\6FUHHQLQ JZLOOLQFOXGH
FRQILUPDWLRQRI066VWDWXVEDVHGRQDQDQDO\VLVRIHLWKHUDUFKL YHGRUIUHVKELRSV\
WLVVXH
0LFURVDWHOOLWHLQVWDELOLW\WHVWLQJLVVWDQGDUGL]HGDQGSHUIRUPH GLQ&OLQLFDO
/DERUDWRU\,PSURYHPHQW$PHQGPHQWVFHUWLILHGODERUDWRULHVZLWKR XWQHHGIRUDVVD\
GHYHORSPHQW 
7KHWHVWZLOOEHSHUIRUPHGXVLQJDFHUWLILHG
LPPXQRKLVWRFKHPLVWU\RUSRO\PHUDVHFKDLQUHDFWLRQEDVHGWHVWVI RUHOLJLELOLW\
7KHVWDUWLQJGRVHRI7$6ZLOOEHPJPGRVHRUDOO\WZLFHGDLO\%,'DQG
PJNJGRVHLQWUDYHQRXVO\HYHU\ZHHNVIRUQLYROXPDE3DWLHQW VZKRDUHHOLJLEOH
ZLOOEHHQUROOHGVHTXHQWLDOO\LQWKHIROORZLQJVWDJHV
6WDJHÂ±7KHILUVWSDWLHQWVZLOOEH HQUROOHGDQGDIWHU&\FOHWUHD WPHQWWKH\ZLOO
EHHYDOXDWHGIRUWKHVDIHW\DQGWROHUDELOLW\RIWKHFRPELQDWLRQ WKHUDS\7$6DQG
QLYROXPDEDUHQRWH[SHFWHGWRKDYHVLJQLILFDQWRYHUODSSLQJWR[L FLWLHV$VDIHW\WHDP
FRPSULVHGRIWKHPHGLFDOPRQLWRUDQGWUHDWLQJLQYHVWLJDWRUVZLO OUHYLHZVDIHW\GDWD
IURPWKHVHILUVWSDWLHQWVDIWHUWKH\KDYHXQGHUJRQH&\FOHW UHDWPHQW,IRUPRUH
SDWLHQWVH[SHULHQFHDGRVHOLPLWLQ JWR[LFLW\'/7WKHQWKHGR VHRI7$6ZLOO
EHUHGXFHGDIWHUGLVFXVVLRQEHWZHHQWKHLQYHVWLJDWRUDQG6SRQV RUDQGDQDGGLWLRQDO
SDWLHQWVZLOOEHHQUROOHG,IWK H'/7LVFRQVLGHUHGUHODWHGW R7$6WKH
LQYHVWLJDWRUVKRXOGIROORZWKHUHFRPPHQGHGGRVHPRGLILFDWLRQVL Q6HFWLRQ ,I
WKH'/7LVFRQVLGHUHGUHODWHGWRQLYROXPDEWKHLQYHVWLJDWRUVK RXOGIROORZWKH
GLVFRQWLQXDWLRQZLWKKROGFULWHULDOLVWHGLQ 6HFWLRQ ,IWKH'/7UHODWLRQVKLSLV
XQFOHDUWRHLWKHU7$6RUQLYROXPDEEXWLVQRWGLVHDVHUHOD WHGWKHQERWK7$6
DQGQLYROXPDEVKRXOGEHLQWHUUXSWHGDQGWKH7$6GRVHVK RXOGEHUHGXFHG
DWWKHQH[WGRVHF\FOH
$FFUXDOZLOOQRWEHKDOWHGZKLOHWKHUHYLHZLVEHLQJFRQGXFWHG LIQR'/7VDUH
LGHQWLILHG$Q\RXWFRPHRIWKLVVDIHW\UHYLHZZLOOEHFRPPXQLFD WHGLQDWLPHO\
PDQQHUWRWKHSDUWLFLSDWLQJLQYHVWLJDWRUVVRWKDWWKH\PD\QRWL I\WKHLU,QVWLWXWLRQDOCCI
CCI
7$6
3URWRFRO1R727$6 0HWDVWDWLF&RORUHFWDO&DQFHU
727$69HUVLRQ-XQH  3DJH RI5HYLHZ%RDUGV
$VVXPLQJDWROHUDWHGGRVHLVFRQILUPHGXSWR'/7LQSDWLHQ WVDWOHDVW
DGGLWLRQDOSDWLHQWVHYDOXDEOH IRUUHVSRQVHZLOOEHHQUROOHGD QGIROORZHGIRUD
PLQLPXPRIPRQWKV$WWKHSRLQ WWKDWWKHQLQWKSDWLHQWLVHQU ROOHGRUDWRWDORIDW
OHDVWSDWLHQWVHYDOXDEOHIRUUHVSRQVHDVVHVVPHQWDWWKHWDUJ HWGRVHHQUROOPHQW
ZLOOVWRSDQGWKHUHZLOOEHDQDVVHVVPHQWRIVDIHW\DQGHIILFD F\WRGHWHUPLQH
ZKHWKHU6WDJHZLOORSHQIRUHQUROOPHQW7RSURFHHGWR6WDJH WZRRUPRUH
SDWLHQWVRXWRIWKHSDWLHQWVLQ6WDJHZLOOQHHGWRGHPRQVW UDWHDSDUWLDOUHVSRQVH
RUFRPSOHWHUHVSRQVHZLWKLQDPRQWKWXPRUIROORZXSSHULRG, IWKHUHDUHIHZHU
WKDQUHVSRQGHUVLQ6WDJHWKHQWKHVWXG\ZLOOEHVWRSSHG
6WDJHÂ±$QDGGLWLRQDOSDWLHQWVHYDOXD EOHIRUUHVSRQVHDVVHVVPHQWZ LOOEH
HQUROOHGDQGIROORZHGIRUDPLQLPXPRIPRQWKV
7KHFRPELQDWLRQRI7$6DQGQLYROXPDELVH[SHFWHGWRWULJJHU 
LPPXQHPHGLDWHGUHVSRQVHVZKLFKUHTXLUHDFWLYDWLRQRIWKHLPPX QHV\VWHPEHIRUH
WKHREVHUYDWLRQRIFOLQLFDOUHVSRQVHV6XFKLPPXQHDFWLYDWLRQP D\WDNHZHHNVWR
PRQWKVWREHFRPHHYLGHQW6RPHSDWLHQWVPD\KDYHDQREMHFWLYHY ROXPHLQFUHDVHRI
1XPEHURI3DWLHQWV
3ODQQHG$SSUR[LPDWHO\WRHYDOXDEOHSDWLHQWVZLOOEHHQUROOHGLQD 6LPRQÂ¶VVWDJH
GHVLJQ
&ULWHULDIRU,QFOXVLRQ
DQG([FOXVLRQ,QFOXVLRQ&ULWHULD
+DVSURYLGHGZULWWHQLQIRUPHGFRQVHQW
3DWLHQWZLWKFRQILUPHGKLVWRORJLFDOO\SURYHQPHWDVWDWLFRUORFD OO\DGYDQFHG
FRORUHFWDODGHQRFDUFLQRPDZKRDUH 066LHQRW06,EDVHGRQHL WKHUDQ
DQDO\VLVRIWLVVXHIURPDSULRUE LRSV\RUEDVHGRQWLVVXHIURP DQHZELRSV\
3DWLHQWZLWKWKHSUHVHQFHRIDWOHDVWOHVLRQZLWKPHDVXUDEOH GLVHDVHDVGHILQHG
E\PPLQWKHORQJHVWGLDPHWHUIRUDVRIWWLVVXHOHVLRQVRU PPLQWKHVKRUW
D[LVIRUDO\PSKQRGHE\5(&,67DQGLU5&FULWHULDIRUDUHVSRQV HDVVHVVPHQW
3DWLHQWKDVUHFHLYHGDWOHDVWSULRUOLQHVRIVWDQGDUGFKHPRWK HUDSLHVIRUP&5&
DQGLVUHIUDFWRU\WRRUIDLOLQJWKRVHFKHPRWKHUDSLHVD6WDQGDUGFKHPRWKHUDS\PXVWLQFOXGH$//RIWKHIROORZLQJDJHQWV 
L)OXRURS\ULPLGLQHVLULQRWHFDQDQGR[DOLSODWLQ
LL$QDQWL9(*)ELRORJLFDOWKHUDS\ HJEHYDFL]XPDERUDIOLEHUFHSW RU
UDPXFLUXPDE
LLL$WOHDVWRIWKHDQWL(*)5PRQRFORQDODQWLERGLHVP$EV
FHWX[LPDERUSDQLWXPXPDEIRU 5$6ZLOGW\SHSDWLHQWV
$JHÂ•\HDUV
(DVWHUQ&RRSHUDWLYH2QFRORJ\*URXSSHUIRUPDQFHVWDWXVRIWR DWWKHWLPHRI
HQUROOPHQW
/LIHH[SHFWDQF\RIÂ•PRQWKV
+DVDGHTXDWHRUJDQIXQFWLRQDVG HILQHGE\WKHIROORZLQJFULWHUL D
D$EVROXWHQHXWURSKLOFRXQWRIÂ•PP
LHÂ•Ã®/E\
,QWHUQDWLRQDO8QLWV>,8@
E3ODWHOHWFRXQWRIÂ•PP,8Â•Ã®/
F+HPRJORELQYDOXHRIÂ•JG/,ISDWLHQWUHTXLUHGSUHYLRXVEO RRG
WUDQVIXVLRQVDKHPRJORELQYDOXHPXVWEHREWDLQHG!ZHHNVDIW HUWKHODVW
EORRGWUDQVIXVLRQ
G$VSDUWDWHDPLQRWUDQVIHUDVH$67DQGDODQLQHDPLQRWUDQVIHUDVH $/7
YDOXHRIÂ”Ã®XSSHUOLPLWRIQRUPDO8/1
H7RWDOVHUXPELOLUXELQYDOXHRIÂ”Ã®8/1
I6HUXPFUHDWLQLQHYDOXHRIÂ”PJG/CCI
TAS-[ADDRESS_17945] (uri ne or 
serum) within [ADDRESS_17946] 
agree to use effective birth co ntrol during the study (before  the first dose and for 
[ADDRESS_17947] dose  of study drugs) if conception is possible during this 
interval. Female patients are c onsidered to not be of childbearing potential if 
they have a histo ry of hysterectomy, or are post menopausal defined as no 
menses for 12 consecutive months without an alternative medical cause. For 
both males and females, see Section 7.7.3 for definitions of contraceptive 
methods considered effective for this protocol.  
10. Is able to take medications orally (ie, study drug must not be administered via a 
feeding tube ). 
11. Willingness  and ability to comply with scheduled visits, treatment plans, 
laboratory tests, and other study procedures.  
Exclusion Criteria  
1. Has a serious  illness or medical condition  including, but not limited to the 
following:  
a. Other concurrently active malignancies excluding malignancies that are 
disease-free for more than 3 years or carcinoma -in-situ deemed cured by 
[CONTACT_19096].  
b. Known brain metastasis or leptomeningeal metastasis.  
c. Active infection (ie, body temperature â‰¥  38Â°C because of  infection) 
including active or unresolved pneumonia/pneumonitis.  
d. Intestinal obstruction, pulmonary fibrosis, renal failure, liver failure, or 
clinically significant cerebrovascular disorder and evidence of interstitial 
lung disease.  
e. Uncontrolled  diabetes. 
f. Myocardial infa rction within 12  months before  enrollment  severe/unstable 
angina, symptomatic congestive heart fail ure [LOCATION_001] Heart Association  
class III or IV  
g. Gastrointestinal hemorrhage  (grade â‰¥ 3) within 2 weeks before  enrollment.  
h. Known human immunodeficiency virus  or acquired immunodeficiency 
syndrome -related illness, or chronic or acute hepatitis B or hepatitis C.  
i. Psychiatric disease that may increase the risk associated with study 
participation or study drug administration, or may interfere with the interpretation of study results.  
j. History of any autoimmune disease: Patients with a history of inflammatory bowel disease, including ulcerative colitis and Crohnâ€™s 
Disease, are excluded from this study, as are patients with a hi story of 
symptomatic disease (eg , rheumatoid arthritis, systemic progressive 
sclerosis [scleroderma], systemic lupus erythematosus , autoimmune 
vasculitis [eg, Wegenerâ€™s Granulomatosis]); central nervous system  or 
motor neuropathy considered of autoimmune origin (eg , Guillain -Barre 
Syndrome and Myasthenia Gravis, multiple sclerosis). Patients with Gravesâ€™ disease will be allowed.  
k. Patients with a condition requiring systemic treatment with either 
corticosteroids (>  20 mg daily prednisone equivalent) or other 
immunosuppressive medications within 14 days of Cycle 1 Day 1. Inhaled or topi[INVESTIGATOR_8826], and adrenal replacement steroids doses â‰¤ 20 mg daily 
prednisone or equivalent, are permitted in the absence of active autoimmune disease.  
2. Treatment with any of the following within the specified time frame before 
enrollment : 
a. Major surgery within the past 4 weeks (the surgical incision should be f ully 
healed before study drug administration).  
b. Any anticanc er therapy within the past  [ADDRESS_17948]  4 weeks or limi ted field radiation 

7$6
3URWRFRO1R727$6 0HWDVWDWLF&RORUHFWDO&DQFHU
727$69HUVLRQ-XQH 3DJH RIZLWKLQWKHSDVWZHHNVEHIRUHHQUROOPHQW
G $Q\LQYHVWLJDWLRQDOGUXJGHYLFHUHFHLYHGZLWKLQWKHSDVWZH HNVRUWLPHV
WKHKDOIOLIHZKLFKHYHULVVKRUWHUEHIRUHHQUROOPHQW
 3UHYLRXVWUHDWPHQWZLWK7$6
 3ULRUWUHDWPHQWZLWKDQWL3'DQWL3'/DQWLSURJUDPPHG FHOOGHDWK
OLJDQGDQWL&'DQWL2;DQWL&'DQWLF\WRWR[LF7
O\PSKRF\WHDVVRFLDWHGDQWLJHQDQWLERGLHVRUDQ\RWKHULPPXQH FKHFNSRLQW
LQKLELWRUV
 8QUHVROYHGWR[LFLW\RI1DWLRQDO&DQFHU,QVWLWXWH1&,&RPPRQ 7HUPLQRORJ\
&ULWHULDIRU$GYHUVH(YHQWV&7&$(YHUVLRQÂ•JUDGHDWWU LEXWHGWRDQ\
SULRUWKHUDSLHVH[FOXGLQJDQHPLDDORSHFLDVNLQSLJPHQWDWLRQ DQG
SODWLQXPLQGXFHGQHXURWR[LFLW\
 3ULRUHYHQWVRILPPXQHPHGLDWHGSQHXPRQLWLVLPPXQHPHGLDWHG FROLWLV
LPPXQHPHGLDWHGKHSDWLWLVLPPXQHPHGLDWHGHQGRFULQRSDWKLHV
LPPXQHPHGLDWHGQHSKULWLVDQGUHQDOG\VIXQFWLRQLPPXQHPHGLDWH GUDVK
LPPXQHPHGLDWHGHQFHSKDOLWLVD QGKLVWRU\RILQIXVLRQUHDFWLRQV WRQLYROXPDE
 .QRZQRUDVVXPHGK\SHUVHQVLWLYLW\WR7$6RUQLYROXPDERU DQ\RILWV
LQJUHGLHQWVLQFOXGLQJSRO\VRUEDWHFRQWDLQLQJLQIXVLRQ
 3UHYLRXVVHYHUHK\SHUVHQVLWLYLW\UHDFWLRQWRWUHDWPHQWZLWKD QRWKHUP$E
 3UHJQDQWRUODFWDWLQJIHPDOH
 ,QDSSURSULDWHIRUHQWU\LQWRWKLVVWXG\LQWKHMXGJPHQWRIW KHLQYHVWLJDWRU
7UHDWPHQW5HJLPHQV 7$6VWDUWLQJGRVHRIPJPGRVHZLOOEHDGPLQLVWHUHGRUDOO\%,'ZLWKLQ
KRXUDIWHUFRPSOHWLRQRIWKHPRUQLQJDQGHYHQLQJPHDOVIRU GD\VDZHHNZLWK
GD\VRIUHVWIRUZHHNVIROORZHGE\DGD\UHVWUHSHDWHG HYHU\ZHHNV
,QDGGLWLRQSDWLHQWVZLOOUHFHLYHQLYROXPDEPJNJLQWUDYHQRX VO\RYHUPLQXWHV
HYHU\ZHHNVRQ'D\DQG'D\RIHDFKF\FOH7KHLQYHVWLJDW RUZLOODWWHPSWWR
NHHSWKHQLYROXPDEVFKHGXOHRQWKHVDPHVFKHGXOHDV7$6HY HQLIWKHUHLVD
GHOD\LQGRVLQJRI7$6
6WXG\'XUDWLRQ 3DWLHQWVZLOOEHWUHDWHGXQWLOWK HSDWLHQWPHHWVWKHGLVFRQWLQX DWLRQFULWHULD
6HFWLRQ 
)RUWKHSXUSRVHRIILQDODQDO\VHVWKHVWXG\ZLOOEHFRQVLGHUHG FRPSOHWHGZKHQDOO
SDWLHQWVKDYHGLVFRQWLQXHGIURPWUHDWPHQWRUPRQWKVDIWHUWK HILUVWGD\RI
WUHDWPHQWZLWK7$6SOXVQLYROXPDERIWKHODVWSDWLHQWHQURO OHGZKLFKHYHU
RFFXUVILUVW8SRQGDWDFXWRIISDWLHQWVRQJRLQJZLWKVWXG\WUH DWPHQWPD\FRQWLQXH
ZLWKWKHLUWUHDWPHQWDQGEHIROORZHGIRUVDIHW\0HDVXUHPHQWVR IHIILFDF\DQGGDWD
FROOHFWLRQPD\EHUHGXFHG
(IILFDF\&ULWHULDIRU
(YDOXDWLRQ&RPSXWHGWRPRJUDSK\VFDQVZLOOEHSHUIRUPHGDWEDVHOLQHDQGWKH QHYHU\F\FOHV
2QVLWHWXPRUDVVHVVPHQWVZLOOEHSHUIRUPHGE\WKHLQYHVWLJDWRU ORFDOUDGLRORJLVW
7XPRUVFDQVZLOOEHDVVHVVHGXVLQJLU5&DQG5(&,67FULWHULD2Y HUDOOUHVSRQVH
UDWH'&53)6DQG26ZLOOEHG HWHUPLQHGIRUDOOSDWLHQWV
6DIHW\&ULWHULDIRU
(YDOXDWLRQ$GYHUVHHYHQWV$(VZLOOEHJUDGHGXVLQJWKH1&,&7&$(CCI
TAS-102 
Protocol No. TO -TAS-102-203 Metastatic Colorectal Cancer  
TO-TAS-102-203 Version 1.0 14 June 2016  Page 7 of 80 Statistical Methods: Study Populations  
The study populations for all analyses are defined as follows : 
â€¢ Safety Population: Includes  all patients who received at least 1  dose of study 
drug. It will be the primary population for safety analyses.  
â€¢ DLT Evaluable Population: Includes  all patients in the safety population in 
Stage 1, prior to confirming the recommended dose, who completed at  least 
1 cycle (28 days) of study treatment with at least 80% of the study treatment 
administered, unless the treatment was interrupted because of a DLT.  
â€¢ Efficacy Population: Includes all patients in the sa fety population who 
completed at least 6  months of tumor follow -up (evaluable irRC and/or 
RECIST assessments), unless the patient  progressed or died before the 6- month 
follow-up. 
Efficacy Analyses  
Tumor response assessments and disease progression will be evaluated in this study 
using the irRC and RECIST  criteria. The RECIST and irRC response assessments 
will be performed by [CONTACT_19097]. Descriptive statistics, such as 
incidence of responses (ORR and DCR),  Kaplan-Meier estimates for PFS and OS, 
and associated 95% confidence intervals will be provided.  
Safety Analyses  
Simple descriptive statistics will be provided for safety endpoints, 
demographic/baseline characteristics, and study drug exposure. Safety endpoints 
will primarily include incidence of AEs and changes from baseline (grade changes) 
in clinical laboratory tests.  
Sample Size 
Justification:  Sample size considerations are based on a 2 -stage minimax Simon design, testing a 
null hypothesis (poor response) of 10% or less immune-related overall response 
(irOR) versus an alternative hypothesis (promising response) of 30% or greater irOR 
at an approximate 5% 1 -sided significance level and 80% power. In Stage 1 (futility 
assessment) , enrollment will include [ADDRESS_17949] 2 of 15 (13%) patients respond (partial 
response or complete response). The probability of early stoppi[INVESTIGATOR_19075] 55%. In St age 2, if the Stage [ADDRESS_17950] 6 of 25 (24%) patients respond.  
If the initial dose is not tolerated in the first 6 patients in Stage 1, an additional 
6 DLT-evaluable patients will be enrolled at the reduced dose. Assuming a 10 to 
15% nonevaluability for DLT and/or irRC assessm ent rate, a total of 30 to 
35 patients is expected to be enrolled in the study.  
Interim Analyses:  The first 6 patients will be enrolled and will be evaluated for the safety and tolerability of the combination therapy  after Cycle 1 .  
In Stage 1, at the point that the ninth patient is enrolled (or a total of at least 15 patients evaluable for response assessment at the target  dose), enrollment will 
stop, and there will be an assessment of safety and efficacy to determine whether the 
second stage will open for enrollment . 
 
7$6
3URWRFRO1R727$6 0HWDVWDWLF&RORUHFWDO&DQFHU
727$69HUVLRQ-XQH  3DJHRI678'<6&+('8/(
7DEOH 6WXG\6FKHGXOH
%DVHOLQH
3HULRG2Q7UHDWPHQW3HULRG(QGRI7UHDWPHQW
(QGRI6WXG \3HULRG
9LVLW,'3URFHGXUH &<&/( 68%6(48(17&<&/(6
(QGRI
7UHDWPHQW'D\
6DIHW\
)ROORZ
XS
9LVLW6XUYLYDO
)ROORZXS%DVHOLQH'D\ 'D\RI&\FOH 'D\RI&\FOH

WR
WR  (QGRI
5HFRYHU\  (QGRI
5HFRYHU\
6LJQ,&) ;         
(QUROOPHQW ;         
0HGLFDO+LVWRU\;         
+LVWRORJLFDO&RQILUPDWLRQ ;          
3K\VLFDO([DPLQDWLRQ;    ;  ;; 
%DVHOLQH6LJQVDQG
6\PSWRPV;           
+HLJKW ;           
9LWDO6LJQV ;     ;  ;  ;  
:HLJKW ;   ;  ;;  ;  ;  
(&2*3HUIRUPDQFH6WDWXV;;  ;   ;;  ;  ;  
+HPDWRORJ\ ; ;  ;;  ;  ;  
6HUXP&KHPLVWU\ ; ;  ;;;  ;  
8ULQDO\VLV ;           
3UHJQDQF\7HVW ;       ; ; 
7XPRU0HDVXUHPHQWV;     ;;  ;
&RQFRPLWDQW0HGLFDWLRQV;  ;
$(6$($VVHVVPHQW ;    
7$67UHDWPHQW; 
';
' ; 
';
'    
1LYROXPDEÂ±HYHU \ZHHNV ;  ;  ;  ;     
CCI
7$6
3URWRFRO1R727$6 0HWDVWDWLF&RORUHFWDO&DQFHU
727$69HUVLRQ-XQH  3DJHRI7DEOH 6WXG\6FKHGXOH&RQWLQXHG
9LVLW,'3URFHGXUH %DVHOLQH
3HULRG2Q7UHDWPHQW3HULRG  (QGRI7UHDWPHQW
(QGRI6WXG \3HULRG
%DVHOLQH'D\ &<&/(  68%6(48(17&<&/(6 
(QGRI
7UHDWPHQW'D\
6DIHW\
)ROORZ
XS
9LVLW6XUYLYDO
)ROORZ
XS'D\RI&\FOH 'D\RI&\FOH

WR
WR(QGRI
5HFRYHU\ (QGRI
5HFRYHU\

6XUYLYDO6WDWXV    ;
(QGRI7UHDWPHQW$VVHVVPHQWVZLOOEHSHUIRUPHGDWWLPHRIWUH DWPHQWGLVFRQWLQXDWLRQRIERWKVWXG\GUXJV7$6DQGQLYROXP DE,IWKHGHFLVLRQWR
GLVFRQWLQXHVWXG\GUXJVLVPDGHZLWKLQZHHNVDIWHUWKHSDWLHQ WÂ¶VODVWWUHDWPHQWYLVLWDQ(QG RI7UHDWPHQWYLVLWLVQRWUHTX LUHGXQOHVVGHHPHGFOLQLFDOO\
QHFHVVDU\E\WKHLQYHVWLJDWRU,IWKHGHFLVLRQWRGLVFRQWLQXHV WXG\GUXJVLVPDGHPRUHWKDQZHHNVDIWHUWKHODVWWUHDWPHQWY LVLWDQ(QGRI7UHDWPHQW9LVLWLV
UHTXLUHG,IWKLVYLVLWRFFXUVZLWKLQZHHNVRIWKHGD\6DI HW\)ROORZXSYLVLWWKHYLVLW VFDQEHFRPELQHGDQGWKHLQIRU PDWLRQDWWKH(QGRI7UHDWPHQWYLVLW
ZLOOEHHQWHUHGLQWRWKHGD\6DIHW\)ROORZXSYLVLW
$VVHVVPHQW:LQGRZV$ZLQGRZRIÂ“GD\VLVDOORZDEOHIRUVWXG \SURFHGXUHVÂ“GD\VDOORZDEOH IRUFRPSXWHUL]HGWRPRJUDSK\>& 7@VFDQVDVORQJDVWKH
SURSHURUGHULVPDLQWDLQHG
6LJQ,QIRUPHG&RQVHQW)RUP,&):ULWWHQLQIRUPHGFRQVHQWVKR XOGEHREWDLQHGEHIRUHWKHSHUIRUPDQFHRIDQ\VWXG\SURFHGXUH
(QUROOPHQW(QUROOSDWLHQWE\HQWHULQJEDVHOLQHGDWDLQWRWKH HOHFWURQLFFDVHUHSRUWIRUPLQR UGHUWRUHFHLYHDXQLTXHGLJL WSDWLHQWQXPEHU
3K\VLFDO([DPLQDWLRQ%HJLQQLQJZLWK&\FOHDQGIRUDOOVXEVH TXHQWF\FOHVSHUIRUPDSK\VLFDOH[DPLQDWLRQZLWKLQKRXUVEH IRUH'D\VWXG\GUXJ
DGPLQLVWUDWLRQ
6XEVHTXHQW&\FOHVÂ•2EWDLQZLWKLQKRXUVEHIRUH'D\VWXG \GUXJDGPLQLVWUDWLRQ%HIRUHVWDUWLQJVXEVHTXHQWF\FOHVYHULI \WKDWSDWLHQWVZLWKWR[LFLWLHV 
KDYHPHWUHVXPSWLRQFULWHULDEHIRUHDGPLQLVWHULQJVWXG\GUXJ 
9LWDO6LJQ0HDVXUHPHQWV%ORRGSUHVVXUHKHDUWUDWHERG\WHPSH UDWXUHUHVSLUDWRU\UDWHEHJLQQLQJZLWK&\FOHDQGIRUDOOV XEVHTXHQWF\FOHVFROOHFWZLWKLQ
KRXUVEHIRUH'D\VWXG\GUXJDGPLQLVWUDWLRQ 
(&2*3HUIRUPDQFH6WDWXV&ROOHFWZLWKLQKRXUVEHIRUH'D\D QG'D\VWXG\GUXJDGPLQLVWUDWLRQIRUDOOF\FOHV 
+HPDWRORJ\6HUXP&KHPLVWU\8ULQD O\VLV+HPDWRORJ\DQGVHUXPF KHPLVWU\ZLOOEHSHUIRUPHGDWEDVHOLQHZLWKLQGD\VEHIRUH'D \RI&\FOH'D\
&\FOHDQG'D\DQG'D\RIHDFKVXEVHTXHQWF\FOHEHIRUHDG PLQLVWUDWLRQRIVWXG\GUXJ8ULQDO\VLVLVUHTXLUHGDW%DVHOLQH DQGWKHUHDIWHUDVFOLQLFDOO\
LQGLFDWHG/DERUDWRU\WHVWUHVXOWVREWDLQHGEHIRUHVLJQLQJ,&) PD\EHXVHGLIWKHUHVXOWVZHUHREWDLQHGZLWKLQGD\VEHIRUH' D\RI&\FOH 
3UHJQDQF\7HVW$SUHJQDQF\WHVWLVUHTXLUHGDW%DVHOLQHZLWKL QGD\VEHIRUH'D\RI&\FOHDQGDWHLWKHUWKH(QGRI7UHD WPHQWRUGD\6DIHW\
)ROORZXSYLVLW0RUHIUHTXHQWSUHJQDQF\DVVHVVPHQWVPD\EHSHU IRUPHGDVUHTXLUHGE\ORFDOODZ
7XPRU0HDVXUHPHQWV2EWDLQDFRQWUDVWHQKDQFHG&7VFDQRIWKHF KHVWDQGDEGRPHQDQGSHOYLVLIFOLQLFDOO\LQGLFDWHGZLWKLQ GD\VEHIRUH'D\RI
&\FOHDQGHYHU\F\FOHVWKHUHDIWHUGXULQJVWXG\WUHDWPHQW, IDSDWLHQWGLVFRQWLQXHVWUHDWPH QWEHFDXVHRIUDGLRORJLFGLVHDV HSURJUHVVLRQDGGLWLRQDOWXPRU
DVVHVVPHQWLVQRWUHTXLUHGDWWKH(QGRI7UHDWPHQWYLVLW)RUS DWLHQWVZKRGLVFRQWLQXHWUHDWPHQWIRUUHDVRQVRWKHUWKDQUDGLRO RJLFGLVHDVHSURJUHVVLRQHYHU\
HIIRUWVKRXOGEHPDGHWRSHUIRUPDQHQGRIWUHDWPHQWWXPRUDVVH VVPHQWEHIRUHWKHVWDUWRIQHZDQWLFDQFHUWKHUDS\3DWLHQWVWKD WGLVFRQWLQXHGWUHDWPHQWIRU
UHDVRQVRWKHUWKDQGLVHDVHSURJUHVVLRQVKRXOGFRQWLQXHWREHIR OORZHGIRUWXPRUUHVSRQVHHYHU\F\FOHVXQWLOWKHSDWLHQWGHYH ORSVUDGLRORJLFGLVHDVH
SURJUHVVLRQRUGHDWKRULQLWLDWLRQRIQHZDQWLFDQFHUWKHUDS\ ZKLFKHYHURFFXUVILUVW7XPRUDVVHVVPHQWVVKRXOGEHSHUIRUPHG DFFRUGLQJWR5HVSRQVHCCI
7$6
3URWRFRO1R727$6 0HWDVWDWLF&RORUHFWDO&DQFHU
727$69HUVLRQ-XQH  3DJH RI(YDOXDWLRQ&ULWHULDLQ6ROLG7XPRUV>5(&,67@YHUVLRQDVZ HOODVLPPXQHUHODWHGUHVSRQVH FULWHULDLU5&&RPSXWHUL]HGWR PRJUDSK\VFDQVREWDLQHG
EHIRUHVLJQLQJWKH,&)PD\EHXVHGLIWKHGDWHRIWKHVFDQLVZ LWKLQGD\VEHIRUH'D\RI&\FOH
&RQFRPLWDQW0HGLFDWLRQV&ROOHFWFRQFRPLWDQWPHGLFDWLRQVIURPW LPHRIVLJQHG,&)WKURXJKWKHGD\6DIHW\)ROORZXSYLVLWLQ FOXGLQJDQ\PHGLFDWLRQV
XVHGWRWUHDWDGYHUVHHYHQWV$(VRUVHULRXV$(V6$(V$WWK HGD\VDIHW\IROORZXSSHULRG FROOHFWGDWHRILQLWLDWLRQRI DQ\QHZDQWLFDQFHUWKHUDS\
&RQFRPLWDQW0HGLFDWLRQV&ROOHFWDQWLFDQFHUWKHUDSLHV
$(6$($VVHVVPHQW0RQLWRUSDWLHQWVIRUDQ\XQWRZDUGPHGLFDOHY HQWVIURPWKHWLPHRIVLJQHG,&)WKURXJKWKHGD\VDIHW\IROO RZXSSHULRGRUXQWLO
LQLWLDWLRQRIQHZDQWLFDQFHUWUHDWPHQWZKLFKHYHUFRPHVILUVW
6WXG\'UXJ7UHDWPHQW3DWLHQWVZLOOEHGLVSHQVHGZLWKVXIILFLHQ WTXDQWLWLHVRI7$6WRVHOIDGPLQLVWHUWZLFHGDLO\RQ'D\V WKURXJKDQGWKURXJKRI
HDFKF\FOH3DWLHQWVZLOOEHLQVWUXFWHGWRUHWXUQDOOXQXVHG7$ 6DQGXVHGNLWVWRWKHLUQH[WFOLQLFYLVLW1LYROXPDEZLOO EHDGPLQLVWHUHGLQWUDYHQRXVO\RQFH
HYHU\ZHHNVRQ'D\DQG'D\RIHDFKF\FOH7KLVVFKHGXOH VKRXOGEHPDLQWDLQHGHYHQLIWKHUHDUHGHOD\VLQWKHGRVLQJRI 7$6
6XUYLYDO6WDWXV2EWDLQVXUYLYDOVWDWXVDOLYHGHDGDWVFKHGXO HGZHHNWLPHLQWHUYDOVXQWLOVWXG\GLVFRQWLQXDWLRQFULWHULDD UHPHW
$EEUHYLDWLRQV$( DGYHUVHHYHQW(&2* (DVWHUQ&RRSHUDWLYH2 QFRORJ\*URXS,&) LQIRUPHGFRQVHQWIRUP6$( VHULRXVDGYHU VHHYHQW

CCI
7$6
3URWRFRO1R727$6 0HWDVWDWLF&RORUHFWDO&DQFHU
727$69HUVLRQ-XQH  3DJH RI7$%/(2)&217(176
 6<1236,6   
 678'<6&+('8/(   
 7$%/(2)&217(176   
 /,672)$%%5(9,$7,216$1''(),1,7,2162)7(506   
 ,1752'8&7,21   
 7$6   
  0HFKDQLVPRI$FWLRQ   
  7$6LQ&RORQ&DQFHU   
  
  7$6&OLQLFDO([SHULHQFH   
 5DWLRQDOHIRU6WXG\D QG6HOHFWLRQRI'RVH   
  8QPHW0HGLFDO1HHG   
  5DWLRQDOHIRU6WXG\'HVLJQ   
  6HOHFWLRQRI7$6'RVH   
 678'<2%-(&7,9(6   
 ,19(67,*$7,21$/3/$1   
 2YHUDOO6WXG\'HVLJQ   
 6WXG\'XUDWLRQ   
 6WXG\3RSXODWLRQ   
  ,QFOXVLRQ&ULWHULD   
  ([FOXVLRQ&ULWHULD   
 7UHDWPHQW$VVLJQPHQW   
  3DWLHQW1XPEHULQJ   
  5DQGRPL]DWLRQ   
  %OLQGLQJ   
  5HSODFHPHQWRI3DWLHQWV   
 'LVFRQWLQXDWLRQRI6WX G\7UHDWPHQW   
  7UHDWPHQW'LVFRQWL QXDWLRQ&ULWHULD   
  (QGRI7UHDWPHQW 3URFHGXUHV   
 'LVFRQWLQXDWLRQIURP6WXG\)ROORZXS   
 2WKHU0HGLFDWLRQVDQG7KHUDSLHV   CCI
7$6
3URWRFRO1R727$6 0HWDVWDWLF&RORUHFWDO&DQFHU
727$69HUVLRQ-XQH  3DJH RI  3URKLELWHG0HGLFDWL RQVDQG7KHUDSLHV   
  &RQFRPLWDQW0HGLFDWLRQ7KHUDSLHV   
  (IIHFWLYH&RQWUDFHSWLRQ'XULQJWKH6WXG\   
 'LHWDU\5HVWULFWLRQV   
 678'<75($70(17   
 'HVFULSWLRQDQG/DEHOLQJ   
  7$6   
  'HVFULSWLRQ   
  6WRUDJH   
  1LYROXPDE   
 6WXG\'UXJ$GPLQLVWUDWLRQ   
  7$67UHDWPHQW5HJLPHQ   
  1XPEHURI7DEOHWVSHU7$6'RVH   
  ,QVWUXFWLRQVIRU3DWLHQW VIRU+DQGOLQJ7$6   
  7$6'RVH0RGLILFDWLRQV   
  'RVH5HGXFWLRQ/HYHOV   
  'RVH0RGLILFDWLRQVLQ5HVSRQVHW R1RQKHPDWRORJLF7R[LFLWLHV   
  'RVH0RGLILFDWLRQVLQ5HVSRQVH WR+HPDWRORJLF7R[LFLWLHV   
  7$6'RVH5HVXPSWLRQ   
  1LYROXPDE7UHDWPHQW5HJLPHQ   
  1LYROXPDE3UHSDUDWLRQD QG$GPLQLVWUDWLRQ   
  1LYROXPDE'RVH0RGLILFDWLRQV   
 7UHDWPHQW&RPSOLDQFH   
 6WXG\'UXJ$FFRXQWDELOLW\   
 678'<$66(660(176   
 $OO6WXG\3URFHGXUHV   
  ,QIRUPHG&RQVHQW   
  0HGLFDO+LVWRU\   
  +LVWRORJLF&RQILUPDWLRQ   
  3K\VLFDO([DPLQDWLRQ   
  %DVHOLQH6LJQVDQG6\PSWRPV   CCI
TAS-102 
Protocol No. TO -TAS-102-203 Metastatic Colorectal Cancer  
TO-TAS-102-203 Version 1.0 14 June 2016  Page 13 of 80 9.1.8.  Performance Status  .....................................................................................................47  
9.1.9.  Clinical Laboratory Evaluations  .................................................................................47  
[IP_ADDRESS].  Hematology  .................................................................................................................48  
[IP_ADDRESS].  Serum Chemistry  ........................................................................................................49  
[IP_ADDRESS].  Urinalysis  ....................................................................................................................49  
9.1.10.  Pregnancy Testing  ......................................................................................................50  
9.1.11.  Tumor Measurements  .................................................................................................50  
9.1.12.  Prior and Concomitant Medications  ...........................................................................51  
9.1.13.  Adverse Event Assessments .......................................................................................51  
9.2. Assessments by [CONTACT_4838]  ..................................................................................................51  
9.2.1.  Baseline Procedures Before Enrollment  .....................................................................51  
[IP_ADDRESS].  Day âˆ’28 through Day âˆ’1  ............................................................................................51  
[IP_ADDRESS].  Day âˆ’7 through Day âˆ’1  ..............................................................................................52  
9.2.2.  On Treatment Period  ...................................................................................................52  
[IP_ADDRESS].  Cycle 1 Day 1  .............................................................................................................52  
[IP_ADDRESS].  Cycle 1 Day 15  ...........................................................................................................52  
[IP_ADDRESS].  Subsequent Cycles - Cycle X Day 1  ...........................................................................53  
[IP_ADDRESS].  Subsequent Cycles â€“ Cycle X Day 15  ........................................................................53  
[IP_ADDRESS].  Every [ADDRESS_17951] Response Criteria .........................................................................................60  
[IP_ADDRESS].  RECIST Target and Non- target Response Assessments  ............................................60  
[IP_ADDRESS].  RECIST Overall Response Assessment  .....................................................................[ADDRESS_17952] Overall Response Assessment  .............................................................62  
7$6
3URWRFRO1R727$6 0HWDVWDWLF&RORUHFWDO&DQFHU
727$69HUVLRQ-XQH  3DJH RI 5(3257,1*6$)(7<,1)250$7,21   
  $GYHUVH(YHQWVDQG6HULRXV$GYHUVH(YHQWV   
  $GYHUVH(YHQWV   
  6HULRXV$GYHUVH(YHQWV   
  5HSRUWLQJRI'HDWKV   
  'LVHDVH3URJUHVVLRQ   
  3UHJQDQF\   
  0HGLFDWLRQ(UURUV   
  2YHUGRVH   
  /DERUDWRU\(YDOXDWLRQV   
  5HSRUWLQJDQG(YDOXDWLRQRI/D ERUDWRU\7HVW5HVXOWV   
  5HSHDW7HVWLQJ   
  3K\VLFDO([DPLQDWLRQDQG3HUIRUPDQFH6WDWXV   
  9LWDO6LJQ0HDVXUHPHQWVDQG%RG\:HLJKW   
 67$7,67,&6   
  6WXG\3RSXODWLRQV   
  6WXG\(QGSRLQWV   
  3ULPDU\(IILFDF\(QGSRLQW   
  6HFRQGDU\(QGSRLQWV   
  $QDO\WLFDO0HWKRGV   
  3DWLHQW'LVSRVLWLRQ%DVHOLQHDQG7 UHDWPHQW&KDUDFWHULVWLFV   
  3DWLHQW'LVSRVLWLRQ   
  3DWLHQW%DVHOLQH&KDUDFWHULVWLFV   
  6WXG\7UHDWPHQW   
  1RQ6WXG\7UHDWPHQWLQWKH6WXG\)ROORZXS3HULRG   
  (IILFDF\$QDO\VLV   
  6DIHW\$QDO\VHV   
  -XVWLILFDWLRQRI6DPSOH6L]H   
  ,QWHULP$QDO\VHV   
 (7+,&6   
  (WKLFDO&RQVLGHUDWLRQV   
  ,QIRUPHG&RQVHQWDQG3DWLHQW,QIRUPDWLRQ   CCI
TAS-[ADDRESS_17953]/Independent Ethics Committee Approval  ......................71  
14. ADMINISTRATIVE CONSIDERATIONS  ..............................................................72  
14.1.  Protocol Amendments  ................................................................................................72  
14.2.  Curriculum Vitae  ........................................................................................................72  
14.3.  Administrative Structure  .............................................................................................72  
14.4.  Monitoring Procedures  ...............................................................................................72  
14.4.1.  Investigatorâ€™s Responsibilities  ....................................................................................72  
14.4.2.  Sponsorâ€™s Responsibilities  ..........................................................................................72  
14.4.3.  Source Documents  ......................................................................................................73  
14.4.4.  Case Report Form  .......................................................................................................73  
14.4.5.  Sponsorâ€™s Audits and Regulatory Inspections  ............................................................[ADDRESS_17954] OF TABLES  
Table 1:  Study Schedule  .............................................................................................................8  
Table 2:  Number of Tablets Per Dose  .......................................................................................39  
Table 3:  TAS-102 Dose Reduction Levels and Number of Tablets per Dose  ..........................40  
Table 4:  TAS-102 Dose Modi fication Criteria for Non -hematologic Toxicities  .....................41  
Table 5:  TAS-102 Dose Hold Criteria for Hematologic Toxicities Related to 
Myelosuppression .......................................................................................................42  
Table 6:  TAS-102 Resumption Criteria for Hematologic Toxicities related to 
Myelosuppression .......................................................................................................42  
Table 7:  Recommended Dose Modifications for Nivolumab ...................................................44  
Table 8:  Hematology Laboratory Parameters  ...........................................................................49  
Table 9:  Serum Chemistry Laboratory Parameters  ...................................................................49  
Table 10:  Derivation of irRC Overall Responses13 .....................................................................58  
Table 11:  Time Point Response for Patients with Target (Â± Non- target) Disease  ......................[ADDRESS_17955] OF FIGURES  
Figure 1: Mechanism of Antitumor Activity of TAS -[ADDRESS_17956] OF ABBREVIATION S AND DEFINITIONS OF TERMS
Abbreviation  Definition  
5-FU 5-fluorouracil 
AE Adverse event  
ALT Alanine aminotransferase (SGPT)  
ASCO American Society of Clinical Oncology  
AST Aspartate aminotransferase (SGOT)  
BID Twice daily  
BSA Body surface area  
BSC Best supportive care 
CI Confidence interval  
CR Complete response 
CT Computed tomography 
CTCAE Common Terminology Criteria for  Adverse Events  
DCR Disease control rate  
DLT Dose-limiting toxicity  
DNA Deoxyribonucleic acid  
ECOG Eastern Cooperative Oncology Group 
eCRF Electronic case report form  
EGFR Epi[INVESTIGATOR_19076]-PET fluorodeoxyglucose positron emission tomography 
FTD Trifluridine  
G-CSF Granulocyte colony- stimulating factor  
GCP Good Clinical Practice  
IB Investigatorâ€™s Brochure  
ICF Informed Consent Form 
ICH International Council for Harmonisation of Technical 
Requirements for Registration of Pharmaceuticals for Human Use 
IEC Independent Ethics Committee  
IRB Institutional Review Board  
irCR Immune-related complete response  
irOR Immune-related overall response  
TAS-102 
Protocol No. TO -TAS-102-203 Metastatic Colorectal Cancer  
TO-TAS-102-203 Version 1.0 14 June 2016  Page 19 of 80 Abbreviation  Definition  
irORR Immune-related overall response rate  
irPD Immune-related progressive disease  
irPR Immune-related partial response 
irRC Immune-related response criteria  
irSD Immune-related stable disease  
IU International units  
KRAS GTPase KRas; V -Ki-ras2 Kirsten rat sarcoma viral oncogene 
homolog 
mAb Monoclonal antibody 
mCRC Metastatic colorectal cancer 
MedDRA  Medical Dictionary for Regulatory Activities  
MRI Magnetic resonance imaging  
MSI Microsatellite instability  
MSS Microsatellite stable  
NCI National Cancer Institute  
NYHA [LOCATION_001] Heart Association  
ORR Overall response rate  
OS Overall survival  
PD Progressive disease  
PD-[ADDRESS_17957] Response Evaluation Criteria in Solid Tumors 
RECOURSE  Refractory Colorectal Cancer Study 
(TPU-TAS-102-301 Phase 3 study; [STUDY_ID_REMOVED]) 
SAE Serious adverse event  
SAP Statistical analysis plan  
SAR Serious Adverse Reaction  
SD Stable disease  
SPD Sum of the products of the [ADDRESS_17958] Upper limit of normal 
VEGF Vascular endothelial growth factor 
TAS-102 
Protocol No. TO -TAS-102-203 Metastatic Colorectal Cancer  
TO-TAS-102-203 Version 1.0 14 June 2016  Page 21 of 80 5. INTRODUCTION 
5.1. TAS-102 
Detailed i nformation on the nonclinical and clinical experience with TAS-102 is provided in the 
Investigatorâ€™s Brochure (IB). 
5.1.1. Mechanism of Action  
TAS-102 is an oral combination  drug of an antineoplastic thymidine- based nucleoside analogue, 
trifluridine (FTD) and a thymidine phosphorylase (TP) inhibitor, tipi[INVESTIGATOR_13071] (TPI ). 
After uptake into cancer cells, FTD is phosphorylated by [CONTACT_19098], further metabolized 
in cells to a deoxyribonucleic acid (DNA) substrate, and incorporated directly into DNA, thereby 
[CONTACT_19099]. When orally administered, FTD is 
rapi[INVESTIGATOR_19077]. Co- administration of T PI, an inhibitor of TP, with 
FTD prevents the rapid degradation of FTD, resulting in a significant increase in systemic 
exposure to FTD. 
Trifluridine incorporation into DNA is markedly higher than that of other nucleoside analogues. 
The degree of incorporation of FTD into DNA ranges from approximately 10-fold up to 700-fold 
greater in comparison with that of 2â€™-deoxy-5-fluorouridine. Trifluridine also exhibits 
thymidylate synthase inhibition .1-6 Results of in vivo studies show ed FTD incorporation into 
DNA to be the primary mechanism of antitumor activity with oral administration. Trifluridine 
alone, when orally administered, is rapi[INVESTIGATOR_19078], 5- trifluoromethyluracil 
by [CONTACT_10216]. Co-administration of TPI [INVESTIGATOR_19079] .7 In preclinical studies, FTD incorporation into 
DNA in tumor was shown to increase with divided daily administration compared with once 
daily administration. Figure 1 shows the mechanism of antitumor activity of TAS-102. 
7$6
3URWRFRO1R727$6 0HWDVWDWLF&RORUHFWDO&DQFHU
727$69HUVLRQ-XQH  3DJH RI)LJXUH 0HFKDQLVPRI$QWLWXPRU$FWLYLW\RI7$6

7$6LQ&RORQ&DQFHU
CCI
7$6
3URWRFRO1R727$6 0HWDVWDWLF&RORUHFWDO&DQFHU
727$69HUVLRQ-XQH  3DJH RI7$6&OLQLFDO([SHULHQFH
3KDVH&OLQLFDO6WXGLHV
2QHGRXEOHEOLQGUDQGRPL]HG3 KDVHVWXG\6WXG\- KDVEHHQFRQGXFWHGLQ
SDWLHQWVZLWKFRORUHFWDOFDQFHUW RFRPSDUH7$6SOXVEHVWVX SSRUWLYHFDUH%6&WRSODFHER
SOXV%6&7$6ZDVDGPLQ LVWHUHGDWDGRVHRIPJPGRVH%,'7KHPRVWIUHTXHQWO\
UHSRUWHGWUHDWPHQWHPHUJHQWDGYH UVHHYHQWV$(VZHUHQHXWURSKL OFRXQWGHFUHDVHGZKLWHEORRG
FHOOFRXQWGHFUHDVHGKHPRJORELQGHFUHDVHGO\PSKRF\WHFRXQWGH FUHDVHGSODWHOHWFRXQW
GHFUHDVHGQDXVHDGLDU[LOCATION_006]HDI DWLJXHDQGGHFU HDVHGDSSHWLWH
7KHPHGLDQRYHUDOOVXUYLYDO26 ZDVPRQWKVLQWKH7$6 JURXSDQGPRQWKVLQWKH
SODFHERJURXS7KHPHGLDQSURJUHVVL RQIUHHVXUYLYDO3)6DVVHV VHGE\DQLQGHSHQGHQWUHYLHZ
FRPPLWWHHZDVPRQWKVIRUWKH 7$6JURXSDQGPRQWKIR UWKHSODFHERJURXS8VLQJ
WKH5HVSRQVH(YDOXDWLRQ&ULWHULD LQ6ROLG7XPRUV5(&,67WKH EHVWWXPRUUHVSRQVHDVVHVVHG
E\DQLQGHSHQGHQWUHYLHZFRPPLWWHH IRUSDUWLDOUHVSRQVH35ZD VUHSRUWHGIRUSDWLHQWVWDEOH
GLVHDVH6'ZDVUHSRUWHGIRU SDWLHQWVSURJUHVVLYHGLVHDVH 3'ZDVUHSRUWHGIRUSDWLHQWV
DQGSDWLHQWVZHUHQRWHYDOXDEOH LQWKH7$6JURXS,QWKH SODFHERJURXS6'ZDVUHSRUWHG
IRUSDWLHQWV3'ZDVUHSRUWH GIRUSDWLHQWV DQGSDWLHQWV ZHUHQRWHYDOXDEOH7KHUHVSRQVH
UDWHZDVLQWKH7$6J URXSDQGLQWKHSODFHERJURXS 7KHGLVHDVHFRQWUROUDWH
'&5ZDVLQWKH7$6 JURXSDQGLQWKHSODFHERJ URXS
3KDVH&OLQLFDO6WXGLHV
6WXG\7387$6ZDVDGRXEOH EOLQGJOREDOVWXG\FRPSDULQ J7$6SOXV%6&DQG
SODFHERSOXV%6&LQUHIUDFWRU\FROR UHFWDOFDQFHU5HIUDFWRU\&R ORUHFWDO&DQFHU6WXG\
>5(&2856(@3DWLHQWVZHUHUDQGRP O\DVVLJQHGLQDU DWLRDQGVWUDWLILHG E\.5$6VWDWXV
ZLOGPXWDQWWLPHVLQFHGLDJQRV LVRIILUVWPHWDVWDVLV PRQWKVÂ•PRQWKVDQGUHJLRQ
5HJLRQ$VLD>-DSDQ@5HJL RQ:HVWHUQ>86DQG(XURSH@$V RI-DQXDU\FXWRII
GDWHSDWLHQWVZH UHUDQGRPL]HGWR7 $6DQGSDWLHQWV ZHUHUDQGRPL]HGWRSODFHER
7ZRSDWLHQWVLQHDF KWUHDWPHQWJURXSGLGQRWUHFHLYHVWXG\ GUXJWKXVSDWLHQWVZHUH
WUHDWHG7$6SODFHER $WRWDORISD WLHQWVKDGGLVFRQWLQXHGVWXG\
WUHDWPHQWDQGSDWLHQW V7$6SODFHERZHUHFRQWLQ XLQJWRUHFHLYHWUHDWPHQW
2YHUDOORISDWLH QWVZHUHGLVFRQWLQXH GEHFDXVHRIFOLQLFD ORUUDGLRORJLFGLVHDVH
SURJUHVVLRQCCI
CCI
7$6
3URWRFRO1R727$6 0HWDVWDWLF&RORUHFWDO&DQFHU
727$69HUVLRQ-XQH  3DJH RI7KHLQFLGHQFHRIWUHDWPHQWUHOD WHG$(VZDVKLJKHULQWKH7$6 JURXSWKDQLQWKHSODFHER
JURXSDQGUHVSHFWLYHO\ DVZDVWKHLQFLGHQFHRIJ UDGHÂ•$(VDQG
UHVSHFWLYHO\,QWKH7 $6JURXSWKHPRVWIUHTXHQWO\ UHSRUWHGJUDGH$(VZHUH
DQHPLDQHXWURSHQLDQHXWURSKLOFRXQWGHFUHDVHG DQGZKLWHEORRGFHOO
GHFUHDVHG7KHPRVWIUHTXHQW O\UHSRUWHGJUDGH$(VZHUH QHXWURSHQLDDQG
QHXWURSKLOFRXQWGHFUHDVHG
,QWKHSODFHERJURXSWKHPRVWIUHTXH QWO\UHSRUWHGJUDGH$(V ZHUHIDWLJXHGHFUHDVHG
DSSHWLWHDQGEORR GDONDOLQHSKRVSKDWD VHLQFUHDVHG 7KHPRVWIUHTXHQWO\UHSRUWHG
JUDGH$(VZHUHJD[COMPANY_003]JOXWDP\OWUDQVIHUDVHLQFUHDVHGDQ GEORRGELOLUXELQLQFUHDVHG

7KHPRVWIUHTXHQWO\UHSRUWHG$ (VOHDGLQJWRGLVFRQWLQXDWLRQLQ WKH7$6JURXS
ZHUHJHQHUDOSK\VLFDOKHDOWKGH WHULRUDWLRQIDWLJXH DQGG\VSQHD7KHPRVW
IUHTXHQWO\UHSRUWHG$(VOHDGLQ JWRGLVFRQWLQXDWLRQLQWKHSODFH ERJURXSZHUHEORRG
ELOLUXELQLQFUHDVHG JHQHUDOSK\VLFDO KHDOWKGHWHULRUDWL RQDVFLWHV
GHFUHDVHGDSSHWLWH KHSDWLFIDLOXUH DEGRPLQDOSD LQDQGDVWKHQLD
$VRIWKHFXWRIIGDWHGHDWKV ZHUHUHSRUWHGLQRISDWLHQW VLQWKH7$6JURXSDQG
RISDWLHQWVLQWKHSODFHERJURXS7 KHRQO\WUHDWPHQWUHODWHGGH DWKZDVD7$6SDWLHQWZKR
GLHGEHFDXVHRIVHSWLFVKRFN
7KHIUHTXHQF\RIVHULRXV$(V6$ (VLQFOXGLQJIDWDOZDV LQWKH7$6JURXSDQG
LQWKHSODFHERJURXS7KHPRV WIUHTXHQWO\UHSRUWHG6$(VL QWKH7$6JURXSZHUH
JHQHUDOSK\VLFDOKHDOWKGHWHULR UDWLRQIHEULOHQH XWURSHQLDDQG DQHPLD
7KHDGGLWLRQRI7$6WR%6&U HVXOWHGLQDVWDWLVWLFDOO\VLJQ LILFDQWLPSURYHPHQWLQ26
FRPSDUHGZLWKSODFHERSOXV%6& 7KHPHGLDQ26ZDVPRQWKVIR UWKH7$6JURXSYHUVXV
PRQWKVIRUWKHSODFHERJURXSDQGVLGHG 37KHSHUFHQWDJHRISDWLHQWV
VXUYLYLQJDW\HDUZDVLQWKH7$6JURXSDQGLQW KHSODFHERJURXS



&RQVLVWHQWZLWKWKHSULPDU\PHF KDQLVPRIDFWLRQRI7$6D
VLJQLILFDQWLQFUHDVHLQ26ZDV GHPRQVWUDWHGLQSDWLHQWVZKRZHU HUHIUDFWRU\IRU)8UHFHLYHGDV
SDUWRIWKHLUODVWUHJLPH QEHIRUHUDQGRPL]DWLRQ
5DWLRQDOHIRU6WXG\DQG6HOHFWLRQRI'RVH
8QPHW0HGLFDO1HHG
&RORUHFWDOFDQFHULVWKHWKLUGP RVWFRPPRQW\SHRIFDQFHUDPRQJ ERWKPHQDQGZRPHQLQWKH
86DQGLVWKHVHFRQGPRVWGHDGO\ ,WLVHVWLPDWHGWKDWLQHY HU\SHRSOHZLOOGHYHORS
FRORUHFWDOFDQFHU,QLWLV SURMHFWHGWKDWWKHUHZLOOEH QHZFDVHVRIFRORQFDQFHUDQG
QHZFDVHVRIUHFWDOFDQFHULQWKH86$SSUR[LPDWHO\ GHDWKVDUHH[SHFWHGLQWKH
86
7$6LVDQRUDOFRPELQDWLRQRI 0)7'DQG073,7KHSULP DU\PHFKDQLVPRIDFWLRQRI
)7'DQDQWLQHRSODVWLFWK\PLGLQH EDVHGQXFOHRVLGHDQDORJLVLQ FRUSRUDWLRQLQWR'1$YLDCCI
7$6
3URWRFRO1R727$6 0HWDVWDWLF&RORUHFWDO&DQFHU
727$69HUVLRQ-XQH  3DJH RISKRVSKRU\ODWLRQUHVXOWLQJLQDGLIIHUHQWF\WRWR[LFPHFKDQLVPI URP)8DQGÂ¶GHR[\
IOXRURXULGLQHXUDFLOEDVHGWK\PLG \ODWHV\QWKDVHLQKLELWRUV
7$6KDVEHHQVKRZQWRVLJQLIL FDQWO\LPSURYH26LQSDWLHQWV ZLWKPHWDVWDWLFFRORUHFWDO
FDQFHUP&5&ZKRKDYHEHHQSUHYLRXVO\WUHDWHGZLWKRUDUHQRW FDQGLGDWHVIRU
IOXRURS\ULPLGLQHR[DOLSODWLQ DQGLULQRWHFDQEDVHGFKHPRWKHU DS\DQDQWLYDVFXODUHQGRWKHOLDO
JURZWKIDFWRU9(*)ELRORJLFDOW KHUDS\DQGDQDQWLHSLGHUPDO JURZWKIDFWRUUHFHSWRU(*)5
WKHUDS\+RZHYHU7$6LVQRWFXUDWLY HDQGWKHYDVWPDMRULW\RISDWL HQWVZLOOHYHQWXDOO\
SURJUHVV+HQFHWKHUHDUHOLPLWH GWKHUDSHXWLFRSWLRQVUHPDLQI RUSDWLHQWVLQWKLVVHWWLQJ
7UHDWPHQWZLWKSHPEUROL ]XPDEDQDQWL 3'DQWLERG\VLPLODUWR QLYROXPDEVKRZHGWKDWLQ
P&5&SDWLHQWVZLWKKLJKPLFURVD WHOOLWHLQVWDELOLW\06,WXPRUV SHPEUROL]XPDEDFWLYLW\ZDV
PXFKKLJKHUWKDQLQP&5&SDWLHQWVZLWKPLFURVDWHOOLWHVWDEOH0 66WXPRUV7KHPHGLDQ3)6
DQG26ZHUHQRWUHDFKHGLQ06,KLJKP&5&SDWLHQWV,QFRQWUDVW WKHPHGLDQ3)6DQG26ZHUH
DQGPRQWKVUHVSHFWLYHO\LQWKHFRKRUWZLWK066P&5&S DWLHQWVKD]DUGVUDWLRIRU3)6
ZDV> 3@DQGKD]DUGVUD WLRIRU26ZDV> 3 @0RUHRYH UWKHRYHUDOO
UHVSRQVHUDWH255IRUP&5&SDWLHQWVZLWK06,KLJKDQG066ZDV DQGUHVSHFWLYHO\
7KHUHIRUHDQDQWL3'DQWLERG \WKHUDSHXWLFDSSURDFKGRHVQRW DSSHDUWREHHIIHFWLYHLQ066
UHIUDFWRU\FRORUHFWDOFDQFHU
5DWLRQDOHIRU6WXG\'HVLJQ


7KHSURSRVHGPHFKDQLVP IRUWKHREVHUYHGDGGLWLYHRUV\QHUJLVWLF HIIHFWLVDQLQF UHDVHLQWXPRU
LPPXQRJHQLFLW\DIWHUWUHDWPHQW ZLWK7$6OHDGLQJWREHWWHU WXPRUUHVSRQVHWRDQWL3'
DQWLERG\WKHUDS\,QFUHDVHGWXPRULPPXQRJHQLFLW\PD\EHWULJJHU HGE\7$6'1$
LQFRUSRUDWLRQ7KLV3KDVHVWXG\ ZLOOH[DPLQHWKLVK\SRWKHVLV 7KLVSUHVHQWVWXG\LVD
PXOWLFHQWHUVLQJOHDUPVDIHW \OHDGLQ3KDVHGHVLJQHYDOXDW LQJWKHVDIHW\DQGHIILFDF\RI
7$6SOXVQLYROXPDELQSDWLHQWVZLWK066UHIUDFWRU\P&5&
1LYROXPDELVD3'EORFNLQJDQWLERG\LQGLFDWHGIRUWKHWUHDWPH QWRIXQUHVHFWDEOHRUPHWDVWDWLF
PHODQRPDPHWDVWDWLFQR QVPDOOFHOOOXQJFDQFHUDQGDGYDQFHGU HQDOFHOOFDUFLQRPD$OWKRXJK
QLYROXPDEKDVQRWEHHQVWXGLHGLQWKH06,P&5&SDWLHQWSRSXODWL RQLWLVFRQVLGHUHGWREHLQD
VLPLODUFODVVDVSHPEUROL]XPDED QGZLOOEHXVHGLQWKLVVWXG\ 1LYROXPDEZDVVHO HFWHGIRUWKLV
FRPELQDWLRQWKHUDS\EHFDXVHLW LVDGPLQLVWHUHGHYHU\ZHHNVZ KHUHDVSHPEUROL]XPDELV
DGPLQLVWHUHGHYHU\ZHHNV7KHUH IRUHQLYROXPDELVDSSURSULDWH WRFRPELQHZLWK7$6
ZKLFKLVDGPLQLVWHUHGRQ DZHHNUHJLPHQ
2YHUDOOUHVSRQVHUDWHLVRQHRI WKHNH\HIILFDF\HYDOXDWLRQVXW LOL]HGLQRQFRORJ\VWXGLHVLQ
SDUWLFXODUVROLGWXPRUVDQGLV FRQVLGHUHGVWDQGDUGDQGZHOOGH ILQHGE\VHYHUDOJXLGDQFHVHJ
(XURSHDQ0DUNHWLQJ$XWKRULW\D QGWKH)RRGDQG'UXJ$GPLQLVWUDWL RQ2YHUDOOUHVSRQVHUDWHLV
XVHGLQWKHHYDOXDWL RQDQGJXLGDQFHRIFDQFHUWUHDWPHQWVDVZHO ODVLQWKHSUHGLFWLRQRIFOLQLFDO
RXWFRPHV,QDGGLWLRQWR255SDWLH QWVZLOODOVREHHYDOXDWHGX VLQJWKHLPPXQHUHODWHG255CCI
TAS-102 
Protocol No. TO -TAS-102-203 Metastatic Colorectal Cancer  
TO-TAS-102-203 Version 1.0 14 June 2016  Page 26 of 80 (irORR) because it is a modification of the ORR and is widely utilized in clinical trials  
evaluating treatments with immune -oncology products. 
Regarding safety profiles of each drug as reflected in their respective US product inserts, 
TAS-102 treatment mainly caused myelosuppressive toxicities in the RECOURSE Phase 3 
study, as well as other AE s at a frequency of â‰¥ 10% for anemia, neutropenia, asthenia/fatigue, 
nausea, thrombocytopenia, decreased appetite, diarrhea, vomiting, abdominal pain, and pyrexia. 
Nivolumab treatment mainly caused rash in patients with  melanoma with a frequency of â‰¥ 20% 
as well as other immune -mediated adverse reactions. Since there is no overlap between the 
2 safety profiles, a dose- escalation design is not essential f or this study but a safety lead-in 
period is necessary to determine the tolerability of TAS -102 in combination with nivolumab. 
5.2.3. Selection of TAS -102 Dose 
TAS-102 (35 mg/m2/dose) will be administered orally BID, within [ADDRESS_17959]. This treatment cycle will be repeated every 4 weeks.  
The safety and tolerability of this TAS -102 regimen was demons trated in a Phase 3, 
multinational, randomized, double-blind study (RECOURSE; TPU- TAS-102-301), in which 
TAS-[ADDRESS_17960] common AEs associated with TAS- 102 treatment were 
myelosuppressive toxicities. Up to 20% of patients receiving TAS-102 experienced grade 3 or 
grade 4 hematologic events related to anemia and neutropenia/leukopenia; however, the 
incidence of febrile neutropenia was low (3.8%). These events were generally manageable with 
reductions in dose, delays in cycle initiation and occasional use of granulocyte colony-
stimulating factor (G -CSF). Only 3 patients discontinued treatment because of hematologic AEs, 
and there was only 1 treatment-related death because of neutropenia-related infection. Events of 
nausea, decreased appetite, diarrhea, and vomiting related to treatme nt were common in the 
TAS-102 group (20.1% to 39.4%); however, these AEs were rarely g rade 3 or grade 4. The 
incidence of stomatitis among patients receiving TAS -102 was 7.9%; g rade 3 or grade 4 events 
of stomatitis were rare (0.4%). In addition, hand-foot syndrome was reported in only 2.3% of 
patients receiving TAS -102 (all grade 1 or grade 2), which was the same percentage reported in 
the placebo arm.   
Trifluridine,  the active principal of TAS-102, is primarily metabolized by [CONTACT_19100]. Nivolumab is a therapeutic monoclonal antibody (mAb), expected 
to be catabolized into amino acids by [CONTACT_19101]. As nivolumab is not a 
cytokine modulator, it is unlikely to have an effect on drug metabolizing enzymes or transporters 
in terms of inhibition or induction. There are no potential mechanisms of pharmacokinetic drug interaction s for the combination of TAS-102 and nivolumab. Furthermore, the mechanism of 
action and the safety profiles of TAS -102 and nivolumab are also quite different. Therefore, the 
recommended dosage of each agent, 35 mg/m
2 for TAS-102 and 3 mg/kg for n ivolumab is  
selected as the starting dose. 
7$6
3URWRFRO1R727$6 0HWDVWDWLF&RORUHFWDO&DQFHU
727$69HUVLRQ-XQH  3DJH RI678'<2%-(&7,9(6
7KHVWXG\ZLOOHYDOXDWHWKHIR OORZLQJREMHFWLYHVLQSDWLHQWVZL WKP&5&UHFHLYLQJ7$6LQ
FRPELQDWLRQZLWKQLYROXPDE
3ULPDU\2EMHFWLYH
x7RHVWLPDWHWKHLU255RI7$6 DQGQLYROXPDEFRPELQDWLRQWKHU DS\LQP&5&
SDWLHQWV
6HFRQGDU\2EMHFWLYHV
x7RFRQILUPWKHUHFRPPHQGHG3KDVH GRVHIRUWKHFRPELQDWLRQWKH UDS\RI7$6
DQGQLYROXPDE
x7RDVVHVVWKHVDIHW\RI7$6 DQGQLYROXPDEJLYHQDVFRPELQDW LRQWKHUDS\
x7RHVWLPDWHWKH255XV LQJ5(&,67YHUVLRQ
x7RHVWLPDWHWKH3)6 EDVHGRQLPPXQHUHODWHGU HVSRQVHFULWHULD LU5&DQG5(&,67
x7RHVWLPDWHWKH'&5XV LQJLU5&DQG5(&,67
x7RHVWLPDWHWKH26
,19(67,*$7,21$/3/$1
2YHUDOO6WXG\'HVLJQ
7KLVLVDPXOWLFHQWHUVLQJOHDUPVDIHW\OHDGLQ3KDVHVWXG\HY DOXDWLQJWKHVDIHW\DQGHIILFDF\
RI7$6SOXVQLYROXPDELQSDWLHQW VZLWK066UHIUDFWRU\P&5& 
3DWLHQWVZLOOXQGHUJRVFUHHQLQJ WRDVVXUHHOLJLELOLW\6FUHHQLQ JZLOOLQFOXGHF RQILUPDWLRQRI066
VWDWXVEDVHGRQDQDQDO\VLVRIH LWKHUDUFKLYHGRUIUHVKELRSV\ WLVVXH
0LFURVDWHOOLWHLQVWDE LOLW\WHVWLQJLVVWDQGD UGL]HGDQGSHUIRUPH GLQ&OLQLFDO/DERUDWRU\
,PSURYHPHQW$PHQGPHQWVFHUWLILH GODERUDWRULHVZLWKRXWQHHGIRU DVVD\GHYHORSPHQW$UFKLYHG
WXPRUVDPSOHVRUQHZO\REWDLQH GELRSVLHVZLOOEH XVHGIRUGHWHU PLQLQJ06,7KHWHVWZLOOEH
SHUIRUPHGXVLQJFHUWLILHGLPPXQRKL VWRFKHPLVWU\RUSRO\PHUDVHFK DLQUHDFWLRQEDVHGWHVWVIRU
HOLJLELOLW\
7KHVWXG\LVD6LPRQÂ¶VVWDJH GHVLJQ3DWLHQWV ZKRDUHHOLJLEO HZLOOEHHQUROOHGVHTXHQWLDOO\LQ
WKHIROORZLQJVWDJHV
6WDJH7KHILUVWSDWLHQWVZ LOOEHHQUROOHGD QGDIWHU&\FOH WUHDWPHQWWKH\ZLOOEHHYDOXDWHG
IRUWKHVDIHW\DQGWROHUDELOLW\ RIWKHFRPELQDWLRQWKHUDS\7$6 DQGQLYROXPDEDUHQRW
H[SHFWHGWRKDYHVLJQLILFDQWRYH UODSSLQJWR[LFLWLHV$VDIHW\W HDPFRPSULVHGRIWKHPHGLFDO
PRQLWRUDQGWUHDWLQJLQYHVWLJDWRU VZLOOUHYLHZVDIHW\GDWDIURP WKHVHILUVWSDWLH QWVDIWHUWKH\
KDYHXQGHUJRQH&\FOHWUHDWPHQW ,IRUPRUHSDWLHQWVH[SHULH QFHDGRVHOLPLWLQJWR[LFLW\CCI
TAS-102 
Protocol No. TO -TAS-102-203 Metastatic Colorectal Cancer  
TO-TAS-102-203 Version 1.0 14 June 2016  Page 28 of 80 (DLT), then the dose of TAS-102 will be reduced (after discussion between the investigator and 
Sponsor) and an additional 6 patients will be enrolled. If the DLT is considered related to 
TAS-102, the investigator sho uld follow the recommended dose modifications in Section  8.2.4. 
If the DLT is considered related to nivolumab, the investigator should follow the 
discontinuation/ withhold criteria  listed in Section 8.2.6. If the DLT relationship is unclear to 
either TAS -102 or nivolumab, but is not disease related, then both TAS-102 and nivolumab 
should be interrupted and the TAS-102 dose should be reduced at the nex t dose cycle.   
Accrual will not be halted while the r eview is being conducted if no DLTs are identified. Any 
outcome of this safety review will be communicated in a timely manner to the participating investigators  so that they may notify their Institution al Review B oards (IRBs).  
Assuming a tolerated dose is confirmed (up to 1 DLT in 6  patients), at least 9  additional patients 
evaluable for response will be enrolled  and followed for a minimum of 6 months. At the point 
that the ninth patient is enrolled (or a total of  at least 15 patients evaluable for response 
assessment at the target  dose), enrollment will stop, and there will be an interim analysis to 
assess the safety and efficacy to determine whether the second stage will open for enrollment. To proceed to Stage 2, two or more patients out of the 15 patients in  Stage 1 will need to 
demonstrate a PR or complete response ( CR) within a 6 -month tumor follow-up period. If there 
are fewer than 2  responders in Stage 1, then the study will be stopped.  
Stage 2: An additional 10 patients evaluable for response assessment will be enrolled and 
followed for a minimum of 6 months.  
The following TAS-102 related AEs will be considered DLTs (only AEs occurring in Cycle 1 
will be DLT evaluable) : 
Hematological toxicities  
1. Grade 4 neutropenia lasting > 7 days 
2. Grade 4 febrile neutropenia and fever â‰¥ 38Â°C for over 1 hour 
3. Grade 4 thrombocytopenia or grade 3 thrombocytopenia associated with bleeding or 
requiring transfusions 
Non-hematological toxicities  
1. Grade 3 or grade 4 non-hematologic toxicity (excluding alopecia, nausea, vomiting, 
diarrhea) 
2. Grade 3 or grade 4 nausea/vomiting lasting > 48 hours and uncontrolled by [CONTACT_19102]-emetic therapy, including serotonin 5-HT3 receptor antagonists (eg, ondansetron) 
3. Grade 3 or grade 4 diarrhea lasting > 48 hours and unresponsive to antidiarrheal 
medication  
Drug-related toxicities  
1. Any drug -related toxicity resulting in > 2 weeks delay in initiation of Cycle 2 (ie, cannot 
start Cycle 2 until Day 43 or later)  
2. Any drug -related toxicity that prevents completion of 80% compliance for either drug in 
Cycle [ADDRESS_17961] and irRC t o determine objective responses.  
TAS-102 (35 mg/m
2/dose) will be administered orally BID, within [ADDRESS_17962], repeated every 4 weeks. Nivol umab (3 mg/kg/dose) will be administered 
intravenously over [ADDRESS_17963] -enhanced computed tomography ( CT) scan of the chest and abdomen (pelvis if 
clinically indicated) within [ADDRESS_17964]  and irRC. 
For patients who discontinue treatment for reasons other than radiologic disease progression, 
every effort should be made to perform an end-of- treatment tumor assessment before the start of 
new anticancer therapy. Patients that discontinue treatment for reasons other than disease 
progression should continue to be followed for tumor response every 2 cycles  until the patient 
develops radiologic disease progression (or death) or initiation of new anticancer therapy (whichever occurs first). Tumor assessments should be performed according RECIST and irRC. If the CT scan was obtained before the patient signed the informed consent form (ICF),  the CT 
scan may be used if the date of the scan is withi n 28 days before Day 1 of Cycle 1. 
Survival status (alive or dead) should be obtained at scheduled 8- week time intervals until study 
discontinuation criteria are met.  
Standard safety monitoring will be performed and AEs will be graded using the National Cancer 
Institute ( NCI) Common Terminology Criteria for Adverse Events ( CTCAE) version 4.03. 
7.2. Study Duration  
Patients will be treated until the patient meets the discontinuation criteria (see Section 7.5).  
For the purpose of final analyses, the study will be considered completed when all patients have discontinued from treatment or [ADDRESS_17965]. Upon data cutoff, patients ongoing 
with study treatment may continue with their treatment and be followed for safety. 
Measurements of efficacy and data collection may be reduced.  
7.3. Study Population  
Approximately 30 to 35 male and female patients with mCRC will be enrolled in a Simonâ€™s 
2-stage design . 
TAS-[ADDRESS_17966] meet all of the following inclusion criteria to be eligible for enrollment in this 
study: 
1. Has provided written informed consent. 
2. Patient with  confirmed  histologically proven metastatic or locally advanced colorectal 
adenocarcinoma who is  MSS (ie, not MSI) based on either an analysis of tissue from a 
prior biopsy or based on tissue from a new biopsy. 
3. Patient with the presence of at least [ADDRESS_17967] include ALL of the following agents: 
i. Fluoropyrimidines, irinotecan, and oxaliplatin 
ii. An anti-VEGF biological therapy ( eg, bevacizumab or aflibercept or ramucirumab)  
iii. At least 1 of the anti- EGFR mAbs (cetuximab or panitumumab) for RAS  wild-type 
patients. 
5. Age â‰¥ 18 years . 
6. Eastern Cooperative Oncology Group (ECOG) performance status  of 0 to 1 at the time of 
enrollment. 
7. Life expectancy of â‰¥ 4 months. 
8. Has adequate organ function as defined by [CONTACT_4868]: 
a. Absolute neutrophil count of â‰¥ 1500/mm3 (ie, â‰¥ 1.5 Ã— 109/L by [CONTACT_19103]  
[IU]). 
b. Platelet count of â‰¥ 100,000/mm3 (IU: â‰¥ 100 Ã— 109/L) 
c. Hemoglobin value of â‰¥ 9.0 g/dL (If patient required previous blood transfusions, a 
hemoglobin value must be obtained > [ADDRESS_17968] blood transfusion.) 
d. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) value of â‰¤ 3.0 
Ã— upper limit of normal (ULN) .  
e. Total serum bilirubin value of â‰¤ 1.5 Ã— ULN 
f. Serum creatinine value of â‰¤ 1.5 mg/dL. 
9. Women of childbearing potential must have a negative pregnancy test (urine or serum) 
within [ADDRESS_17969] agree to use 
effective birth control during the study (before the first dose and for [ADDRESS_17970] dose of study drug s) if conception is possible during this interval. Female patients are 
considered to not be of childbearing potential if they have a history of hysterectomy, or 
are postmenopausal defined as no menses for 12 consecutive months without an 
alternative medical cause. For both males and females, see Section 7.7.3 for definitions of 
contraceptive methods considered effective for this protocol. 
TAS-102 
Protocol No. TO -TAS-102-203 Metastatic Colorectal Cancer  
TO-TAS-102-203 Version 1.0 14 June 2016  Page 31 of 80 10. Is able to take medications orally (ie, study drug must not be administered via a feeding 
tube). 
11. Willingness and ability  to comply with scheduled visits, treatment plans, laboratory tests, 
and other study procedures. 
7.3.2. Exclusion Criteria  
1. Has a serious illness or medical  condition including, but not limited to the following: 
a. Other concurrently active malignancies excluding malignancies that are disease- free 
for more than 3 years or carcinoma -in-situ deemed cured by [CONTACT_19096] .  
b. Known brain metastasis or leptomeningeal metastasis . 
c. Active infection (ie, body temperature â‰¥ 38Â°C because of infection) including active 
or unresolved pneumonia/pneumonitis. 
d. Intestinal obstruction, pulmonary fibrosis, renal failure, liver failure, or clinically 
significant cerebrovascular disorder and evidence of interstitial lung disease. 
e. Uncontrolled diabetes. 
f. Myocardial infarction within 12 months before enrollment, severe/unstable angina,  
symptomatic congestiv e heart failure [LOCATION_001] Heart As sociation class III or IV 
. 
g. Gastrointestinal hemorrhage (grade â‰¥ 3) within 2 weeks before enrollment. 
h. Known human immunodeficiency virus or acquired immunodeficiency 
syndrome- related illness, or chronic or acute hepatitis B or hepatitis C . 
i. Psychiatric disease that may increase the risk associated with study participation or 
study drug administration, or may interfere with the interpretation of study results . 
j. History of any autoimmune disease: Patients with a history of inflammatory bowel disease, including ulcerative colitis and Crohnâ€™s Disease, are excluded from this study, as are patients with a history of symptomatic disease (eg , rheumatoid arthritis, 
systemic progressive sclerosis [scleroderma], systemic lupus erythema tosus, 
autoimmune vasculitis [eg , Wegenerâ€™s  Granulomatosis]); central nervous system or 
motor neuropathy consider ed of autoimmune origin (eg , Guillain -Barre Syndrome 
and Myasthenia Gravis, multiple sclerosis). Patients with Graves â€™ disease will be 
allowed. 
k. Patient with a condition requiring systemic treatment with either corticosteroids (> 20 mg daily prednisone equivalent) or other immunosuppressive medications 
within 14 days of Cycle 1 Day 1. Inhaled or topi[INVESTIGATOR_8826], and adrenal re placement 
steroids doses â‰¤ 20 mg daily prednisone or equivalent , are permitted in the absence of 
active autoimmune disease.  
2. Treatment  with any of the following within the specified time frame before enrollment: 
a. Major surgery within the past 4 weeks (the surgical incision should be fully healed 
before study drug administration) . 
b. Any anticancer therapy within the past [ADDRESS_17971] 2 weeks before enrollment . 
d. Any investigational drug/device received within the past 4 weeks or 5 times the 
half-life (whichever is shorter) before enrollment. 

TAS-102 
Protocol No. TO -TAS-102-203 Metastatic Colorectal Cancer  
TO-TAS-102-203 Version 1.0 14 June 2016  Page 32 of 80 3. Previous treatment with TAS -102. 
4. Prior treatment with anti- PD-1, anti-PD-L1, anti- programmed cell death ligand -2, 
anti-CD137, anti- OX-40, anti-CD40, anti-cytotoxic T lymphocyte- associated antigen -4 
antibodies, or any other immune checkpoint inhibitors. 
5. Unresolved toxicity of  NCI CTCAE â‰¥ grade 2 attributed to any prior therapi[INVESTIGATOR_014] (excluding 
anemia, alopecia, skin pi[INVESTIGATOR_371], and platinum-induced neurotoxicity). 
6. Prior events of immu ne-mediated pneumonitis, immune- mediated colitis, immune -
mediated hepatitis, immune -mediated endocrinopathies, immune-mediated nephritis and 
renal dysfunction, immune-mediated rash, immune-mediated encephalitis, and history of 
infusion reactions to nivolumab. 
7. Known or assumed hypersensitivity to TAS-102 or nivolumab or a ny of its ingredients, 
including polysorbate 80-containing infusion. 
8. Previous severe hypersensitivity reaction to treatment w ith another mA b. 
9. Pregnant or lactating female. 
10. Inappropriate for entry into this study in the judgment of the investigator. 
7.4. Treatment Assignment  
7.4.1. Patient Numbering  
Study sites will enter patient demographic and bas eline data into the electronic case report f orm 
(eCRF) in order to receive a patient number.  
The eCRF will assign each patient a unique patient number. All patient numbers will be 6 digits; the first [ADDRESS_17972] 3 digits will be the patientâ€™s number. This 
patient number will be maintained throughout the study and will not be reassigned. Patients who 
withdraw consent or discontinue from the study after being assigned a patient number will retain 
their initial number.  
Study drug  administration should begin within 3 calendar days after enrollment as described 
in Section  8. 
For patients who sign an ICF but are not enrolled  and patients who are enrolled but never dosed, 
see the eCRF Completion Guidelines  for instruction on which eCRF pages  to complete.  
7.4.2. Randomization 
This is not a randomized study design. 
7.4.3. Blinding 
This is an open-label design study.  7.4.4. Replacement of Patients  
Patients will not be replaced. An adequate number of patients will be enrolled until the 
pre-specified number of evaluable patients at each stage is met.  
TAS-102 
Protocol No. TO -TAS-102-203 Metastatic Colorectal Cancer  
TO-TAS-102-203 Version 1.0 14 June 2016  Page 33 of 80 7.5. Discontinuation of Study Treatment  
Patients will receive study drug  until a discontinuation criterion is met. 
A patient is considered discontinued from study treatment when the decision to permanently stop 
both study treatments  is made, including those decisions made during study drug interruptions 
and recovery periods.  
Study drugs should be continued whenever possible. In case study drug  is stopped, it should be 
determined if the stop can be made temporarily; permanent study drug  discontinuation should be 
a last resort. Any study drug  discontinuation should be fully documented. 
7.5.1. Treatment Discontinuation Criteria  
The reason for discontinuation of treatment should be documented in the patient s ource 
documents. 
Patients can be discontinued from treatment for the following reasons: 
â€¢ Patient request at any time irrespective of the reason  
â€¢ Patients with tumor progression by [CONTACT_19104]  
â€¢ Clinical progression 
â€¢ Patient experiences an irreversible, treatment -related, grade 4, clinically relevant, 
non-hematologic event  
â€¢ Unacceptable AEs, or change in underlying condition such that the patient can no 
longer tolerate therapy, including: 
a. A maximum dose delay >  28 days from the scheduled start date of the next cycle  
b. Need for more than 3 dose reductions of TAS -102 (or minimum 20 mg/m2/dose 
BID) 
c. Discontinuation of both TAS-102 and nivolumab; patient may be considered for 
continuation of nivolumab or TAS-102 single therapy  at the investigatorâ€™s 
discretion  
â€¢ Physicianâ€™s decision including need for other anticancer therapy not specified in the 
protocol or surgery or radiotherapy to the only site(s) of disease being evaluated in 
this protocol 
â€¢ Pregnancy  
7.5.2. End of Treatment Procedures  
Upon discontinuation of treatment the investigator must:  
â€¢ Notify the clinical research associate immediately  
â€¢ Complete the Study Treatment Discontinuation Form in the eCRF, specifying the 
reason for the patientâ€™s withdrawal from treatment  
â€¢ If a patient is discontinued because of  clinical progression, associated nonserious AEs 
should be reported on the treatment discontinuation page of the eCRF 
7$6
3URWRFRO1R727$6 0HWDVWDWLF&RORUHFWDO&DQFHU
727$69HUVLRQ-XQH  3DJH RI'LVFRQWLQXDWLRQIURP6WXG\)ROORZXS
)RUSDWLHQWVZKRGLVFRQWLQXHVWXG\ WUHDWPHQWIRULU5&GLVHDVHS URJUHVVLRQDGGLWLRQDOWXPRU
DVVHVVPHQWVDUHQRWU HTXLUHGDWWKH(QGRI 7UHDWPHQWYLVLW 
)RUSDWLHQWV
ZKRGLVFRQWLQXHWUHDWPH QWIRUUHDVRQVRWKHUWK DQLU5&GLVHDVHS URJUHVVLRQHJLQWROHUDEOHVLGH
HIIHFWVHYHU\HIIRUWVKRXOGEH PDGHWRSHUIRUPDQHQGRIWUHD WPHQWWXPRUDVVHVVP HQWEHIRUHWKH
VWDUWRIQHZDQWLFDQFHUWKHUDS\ 3DWLHQWVWKDWGLVFRQWLQXHWUHD WPHQWIRUUHDVRQVRWKHUWKDQGLVHDVH
SURJUHVVLRQVKRXOGFRQWL QXHWREHIROORZHGIRUWXPRUUHVSRQVHH YHU\F\FOHVXQWLOWKHSDWLHQW
GHYHORSVLU5&GLVHDVHSURJUH VVLRQRUGHDWKRULQLWLDWLRQRIQ HZDQWLFDQFHUWKHUDS\ZKLFKHYHU
RFFXUVILUVW
$OOWUHDWHGSDWLHQWVZ LOOEHIROORZHGIRUVXU YLYDOHYHU\ZHHN VXQWLOVWXG\GLVFRQWLQXDWLRQ
FULWHULDDUHPHWXQOHVVWKHSD WLHQWKDVZLWKGUDZQFRQVHQWIURP WKHWULDO3DWLHQWVPD\UHTXHVW
GLVFRQWLQXDWLRQRIVWXG\WUHDWPH QWEXWDJUHHWRVXUYLYDOIROORZ XSWKLVLVQRWFRQVLGHUHG
ZLWKGUDZDORIFRQVHQWIURPWKHW ULDO7KHLQYHVWLJDWRUVKRXOG PDNHHYHU\HIIRUWWRFRQWDFWWKH
SDWLHQWRUSULPDU\FDUHJLYHUWRGH WHUPLQHWKHSDWLHQWÂ¶VVXUYLYD OVWDWXV7LPHVDQGGDWHVRIFRQWDFW
PXVWEHGRFXPHQWHGLQWKH SDWLHQWÂ¶VUHFRUGV
$SDWLHQWZLOOEHFRQV LGHUHGGLVFRQWLQXHGIURPVWXG\IROORZXS ZKHQRIWKHIROORZLQJRFFXUV
x3DWLHQWGLHV
x7ZHOYHPRQWKVDIWHUWKHODVWSD WLHQWLVHQUROOHGDQGWKHILQDO DQDO\VLVLVSHUIRUPHG
x6WXG\LVWHUPLQDWHGE\WKH6 SRQVRURUUHJXODWRU\DJHQFLHV
2WKHU0HGLFDWLRQVDQG7KHUDSLHV
3URKLELWHG0HGLFDWLRQVDQG7KHUDSLHV
3DWLHQWVDUHQRWSHU PLWWHGWRUHFHLYHDQ\RWKHULQYHVWLJDWLRQDO RUDQ\RWKHUDQWLFDQFHUWKHUDS\
LQFOXGLQJFKHPRWKHUDS\LPPXQRWKH UDS\LPPXQRVXSSUHVVLYHDJHQWV ELRORJLFDOUHVSRQVH
PRGLILHUVRUHQGRFULQHWKHUDS\ H[FHSWIRUPHJHVWURODFHWDWHD QGVWHURLGVDWGRVHVOHVVWKDQRU
HTXDOWRPJRISUHGQLVRQHHTXL YDOHQWSHUGD\IRUÂ”ZHHNV GXULQJWKHVWXG\WUHDWPHQW
SHULRG
3DOOLDWLYHUDGLRWKHUDS\LVQRWSH UPLWWHGZKLOHWKH SDWLHQWLVU HFHLYLQJVWXG\WUHDWPHQW
&RQFRPLWDQW0HGLFDWLRQ7KHUDSLHV
&DXWLRQLVUHTXLUHGZKHQXVLQJGU XJVWKDWDUHKXPDQWK\PLGLQHN LQDVHVXEVWUDWHVHJ
]LGRYXGLQH6XFKGUXJVLIXVHGF RQFRPLWDQWO\ZLWK7$6PD\ FRPSHWHZLWKWKHHIIHFWRU
)7'IRUDFWLYDWLRQYLDWK\PLGLQ HNLQDVHV7KHUHIRUHZKHQXVLQ JDQWLYLUDOGUXJVWKDWDUHKXPDQ
WK\PLGLQHNLQDVHVXEVWUDWHVPRQ LWRUIRUSRVVLEOHGHFUHDVHGHII LFDF\RIWKHDQWLYLUDODJHQWDQG
FRQVLGHUVZLWFKLQJWRDQDOWHUQDWLYHDQWLYLUDODJHQWWKDWLVQR WDKXPDQWK\PLGLQHNLQDVH
VXEVWUDWHVXFKDVODPLYXGLQH ]DOFLWDELQHGL GDQRVLQHDQGDED FDYLU
7KHIROORZLQJPHGLFDWLRQVPD\EHJLYHQFRQFRPLWDQWO\XQGHUWKH IROORZLQJJXLGHOLQHVCCI
TAS-102 
Protocol No. TO -TAS-102-203 Metastatic Colorectal Cancer  
TO-TAS-102-203 Version 1.0 14 June 2016 Page 35 of 80 Hematologic Support 
Administer hematologic support as medically indicated (eg, blood transfusions, G- CSF, 
erythropoie tin) according to the institutional site standards. If there ar e no  standard procedures 
for the use of growth factors, follow American Soc iety of Clinical Oncology  (ASCO) 2015 
Guidelines for Use of Hematopoietic Colony-S timulating Factors, available 
at http://www.instituteforquality.org/practice
-guidelines. 
Management of Diarrhea  
Educate both patients and patientsâ€™ families regarding the potential seriousne ss of 
chemotherapy -induced diarrhea. Instruct patients to immediately contact [CONTACT_19105]. 
Provide patients with loperamide or other standard antidiarrheal therapy and instruct the patient 
on how to use it at the first sign of di arrhea. 
Monitor the patientâ€™s fluid and electrolyte balance, with appropriate intervention as clinically 
indicated with fluids and electrolyte replacement, antibiotics, and antiemetics.  
Infection prophylaxis with oral antibiotics must be considered for pat ients with persistent 
diarrhea beyond 24 hours, or coincident with g rade â‰¥ [ADDRESS_17973] agree to use effective birth co ntrol during the study (before the first 
dose and for [ADDRESS_17974] dose) if conception is possible during this interval. Female 
patients who are considered not to be of childbearing potential must have a history of being postmenopausal (no menses for 12 consecutive months without an alternative medical cause ), or 
hysterectomy that is clearly documented in the patientâ€™s source documents.  
For women of childbearing potential, including female study participants and partners of male 
participants, effective contraception is defined as  follows: 
â€¢Combined (estrogen and progestogen containing) hormonal contraception associatedwith inhibition of ovulation:
âˆ’ Oral
âˆ’ Intravaginal
âˆ’ Transdermal
â€¢Progestogen -only hormonal contraception associated with inhibition of ovulation:
âˆ’ Oral
TAS-102 
Protocol No. TO -TAS-102-203 Metastatic Colorectal Cancer  
TO-TAS-102-203 Version 1.0 14 June 2016  Page 36 of 80 âˆ’ Injectable  
âˆ’ Implantable 
â€¢ Intrauterine device  
â€¢ Intrauterine hormone- releasing system  
â€¢ Bilateral tubal occlusion  
â€¢ Vasectomized partner with documentation of the success of t he vasectomy  
â€¢ Complete abstinence from heterosexual intercourse (periodic abstinence is not a safe 
method) 
Male patients with partners who are women of childbearing potential should use a combination 
of male condom with a cap, diaphragm, or sponge with sper micide during the trial and for 
[ADDRESS_17975] dose of study drug. 
7.8. Dietary Restrictions  
TAS-102 should be taken with a glass of water within 1 hour after completion of the morning 
and evening meals. There are no dietary restrictions for nivolumab. 
8. STUDY TREATMENT  
At the beginning of each patient treatment cycle, study sites will weigh the patient and calculate 
the patientâ€™s body surface area (BSA), and determine the recommended study drug dosage. No 
increase in dose because of an  increase in BSA is permitted.  
The BSA will be calculated using the following DuBois formula (all BSA calculations are 
rounded to 2 decimal places) or institutional standards at the respective study site . 
BSA (mÂ²) = ([Body Weight (kg)]0.425 Ã— [Height (cm)]0.725) Ã— 0.007184 
Please note the following: 
â€¢ Dose escalations ( for TAS-102, on a mg/m2 basis) of study drugs are not permitted at 
any time 
â€¢ Only 3 dose reductions of TAS-102 are permitted. There will be no dose reductions 
for nivolumab. 
â€¢ Only a â‰¤ 28-day dela y in the start of the next treatment cycle for TAS-102 is 
permitted (see Section [IP_ADDRESS]). 
Study treatment should be started within 3  calendar days after enrollment and should be 
administered as outlined in the following sections of the protocol. The investigator always has the right to deviate from the established rules for dose modification at her/his discretion if he  or 
she believes a more conservative approach is needed in the management of related or unrelated 
AEs. However, doses must be modified at least to the extent specified in Section  8.2.4. All 
deviations from protocol-specified dose modifications must be documented. 
Patients will receive study drugs until one of the discontinuation criteria listed in Section 7.5.1 is 
met. 
7$6
3URWRFRO1R727$6 0HWDVWDWLF&RORUHFWDO&DQFHU
727$69HUVLRQ-XQH  3DJH RI'HVFULSWLRQDQG/DEHOLQJ
7$6
$GHVFULSWLRQRIWKHVWXG\GUXJ DQGWKHUHFRPPHQGHGVWRUDJHFRQ GLWLRQVDUHSURYLGHG
LQ6HFWLRQ DQG6HFWLRQ UHVSHFWLYHO\ 

3DWLHQWVZLOOEHGLVSHQVHG7$6 DWWKHEHJLQQLQJRIHDFKF\F OH(DFKNLWZLOOEHODEHOHGZLWK
LQIRUPDWLRQLQFOXGLQJWKHIROORZLQJ
x3URWRFRO1XPEHU
x6SRQVRUQDPH
x6WRUDJHFRQGLWLRQV
x'LUHFWLRQVIRUXVH
x,QYHVWLJDWLRQDOFDXWLRQVWDWHPHQW
$GGLWLRQDOVWDWHPHQWVZLOOEHSU LQWHGRQWKHODEHOVDVUHTXLU HGE\ORFDOUHJXODWLRQ6WXG\GUXJ
ZLOOEHVKLSSHGIURPDUHJLRQDOGL VWULEXWLRQFHQWHUGLUHFWO\WR FOLQLFDOVLWHV
'HVFULSWLRQ

7$6LVIRUPXODWHGDVDQLPPHGL DWHUHOHDVHILOPFRDWHGWDEOH WZKLFKLVVXSSOLHGLQ
VWUHQJWKVH[SUHVVHGDV)7'FRQWHQW
x7KHPJZKLWHURXQGELFRQYH[WD EOHWFRQWDLQVPJ)7'DQG PJ73,DV
DFWLYHLQJUHGLHQWV
x7KHPJSDOHUHGURXQGELFRQYH [WDEOHWFRQWDLQVPJ)7'D QGPJ73,DV
DFWLYHLQJUHGLHQWV
x%RWKWDEOHWVWUHQJWKVFRQWDLQWKH IROORZLQJLQDFWLYHLQJUHGLHQW VODFWRVHPRQRK\GUDWH
SUHJHODWLQL]HGVWDUF KVWHDULFDFLGK\SURPHOORVHWLWDQLXPGLR [LGHSRO\HWK\OHQH
JO\FRODQGPDJQHVLXPVWHDUDWH
x7KHPJWDEOHWFRQWDLQVWKHI ROORZLQJDGGLWLRQDOLQDFWLYHLQJ UHGLHQWUHGIHUULF
R[LGH
6WRUDJH

$OOVWXG\GUXJPXVWEHNHSWLQD ORFNHGDUHDZLWKDFFHVVUHVWUL FWHGWRVSHFLILFVWXG\SHUVRQQHO
1LYROXPDE
&RPPHUFLDOO\DYDLODEOHQLYROXPDE23',92ÂŠLVDYDLODEOHDV
xPJP/VLQJOHGRVHYLDO
xPJP/VLQJOHGRVHYLDOCCI
CCICCI
TAS-102 
Protocol No. TO -TAS-102-203 Metastatic Colorectal Cancer  
TO-TAS-102-203 Version 1.0 14 June 2016  Page 38 of 80 will be used for the TO -TAS-102-203 study. The drug description and storage information can 
be found in the Patient Package Insert of the commercial label.  
Nivolumab, which will be supplied in an approved commercial package ( single vials in 
individual cartons) , will be labeled with information including the following:  
â€¢ Protocol Number 
â€¢ Sponsor name 
â€¢ Investigational caution statement  
Additional statements will be printed on the label(s) as required by [CONTACT_19106]. Study drug 
will be shipped from a regional distribution c enter directly to clinical sites.  
All study drug must be kept in a locked area with access restricted to specific study personnel. 
8.2. Study Drug  Administration  
8.2.1. TAS-102 Treatment Regimen 
Each treatment cycle will be 28 days in duration. TAS-102 dosage is calculated according to 
BSA. 
One TAS -102 treatment cycle consists of the following:  
â€¢ Days 1 through 5: TAS-102 (35 mg/m2/dose) orally BID 
â€¢ Days 6 through 7: rest  
â€¢ Days 8 through 12: TAS -102 (35 mg/m2/dose) orally BID 
â€¢ Days 13 through 28: rest 
Study drug should be taken only on Days 1-5 and 8-12 of each cycle. If doses are missed or held on those days, the patient should not make up for missed doses. 
Patients should begin taking TAS-102 (Day 1) with the morning dose. Both the morning and 
evening doses should be taken at approximately the same time every day. TAS -102 should be 
taken with a glass of water within 1 hour after completion of the morning and evening meals. 
8.2.2. Number of Tablets per TAS -102 Dose  
TAS-102 tablet calculation is presented in  Table 2, which shows the number of tablets that are 
needed per calculated BSA . 
â€¢ Study drug  should only be given on Days 1 through 5 and Days 8 through 12 of each 
cycle even if doses are missed or held  for any reason during Days 1 through 12. 
â€¢ Extension of study treatment into Days [ADDRESS_17976] period (Days 13 
through 28) is not permitted.  
TAS-102 
Protocol No. TO -TAS-102-203 Metastatic Colorectal Cancer  
TO-TAS-102-203 Version 1.0 14 June 2016  Page 39 of 80 Table 2: Number of Tablets Per Dose  
TAS-102 Dose 
(2 Ã— daily) BSA 
(m2) Dosage in mg  
(2 Ã— daily) Total daily 
dose (mg)  Tablets Per Dose  
15 mg 20 mg 
35 mg/m2 < 1.07 35 70 1 1 
1.07 - 1.22 40 80 0 2 
1.23 - 1.37 45 90 3 0 
1.38 - 1.52 50 100 2 1 
1.53 - 1.68 55 110 1 2 
1.69 - 1.83 60 120 0 3 
1.84 - 1.98 65 130 3 1 
1.99 - 2.14 70 140 2 2 
2.15 - 2.29 75 150 1 3 
â‰¥ 2.30 80 160 0 4 
Abbreviation: BSA=body surface area (calculate to 2 decimal places) . 
8.2.3. Instructions for Patients for Handling TAS-[ADDRESS_17977] be instructed in the handling of TAS-102 as follows: 
â€¢ To store the study drug at room temperature 
â€¢ To only remove from the study drug  kit the amount of tablets needed at the time of 
dosing 
â€¢ To wash their hands after handling study drug  
â€¢ Not to remove doses in advance of the next scheduled dosing 
â€¢ To make every effort to take doses on schedule  
â€¢ To report any missed doses 
â€¢ To take study drug within 1 hour after completing a meal (morning and evening meal) 
with a glass of water 
â€¢ If the patient vomits after taking study drug, the patient should not take another dose 
â€¢ To keep study drug  in a safe place and out of reach of children  
â€¢ To bring all used and unused study drug kits to the site at each visit 
8.2.4. TAS-102 Dose Modifications 
[IP_ADDRESS]. Dose Reduction Levels  
TAS-102 dose reductions to be applied in case of toxicity and the number of tablets for each 
calculated BSA are described in  Table 3. Patients are permitted dose reduction(s) to a minimum 
dose of 20 mg/m2 (40 mg/m2/day) in 5 mg/m2 steps. 
TAS-102 
Protocol No. TO -TAS-102-203 Metastatic Colorectal Cancer  
TO-TAS-102-203 Version 1.0 14 June 2016  Page 40 of 80 Table 3: TAS-102 Dose Reduction Levels and Number of Tablets per Dose  
TAS-102 
Dose (2 Ã— 
daily) BSA 
(m2) Dosage in mg  
(2 Ã— daily) Total daily 
dose (mg)  Tablets per Dose  
15 mg 20 mg 
Level 1 Dose Reduction: From 35 mg/m2 to 30 mg/m2 
30 mg/m2 < 1.09 30 60 2 0 
1.09 - 1.24 35 70 1 1 
1.25 - 1.39 40 80 0 2 
1.40 - 1.54 45 90 3 0 
1.55 - 1.69 50 100 2 1 
1.70 - 1.94 55 110 1 2 
1.95 - 2.09 60 120 0 3 
2.10 - 2.28 65 130 3 1 
â‰¥ 2.29 70 140 2 2 
Level 2 Dose Reduction: From 30 mg/m2 to 25 mg/m2 
25 mg/m2 < 1.10 25a 50a 2 (PM)a 1 (AM)a 
1.10 - 1.29 30 60 2 0 
1.30 - 1.49 35 70 1 1 
1.50 - 1.69 40 80 0 2 
1.70 - 1.89 45 90 3 0 
1.90 - 2.09 50 100 2 1 
2.10 - 2.29 55 110 1 2 
â‰¥ 2.30 60 120 0 3 
Level 3 Dose Reduction: From 25 mg/m2 to 20 mg/m2 
20 mg/m2 < 1.14 20 40 0 1 
1.14 â€“ 1.34 25a 50a 2 (PM)a 1 (AM)a 
1.35 â€“ 1.59 30 60 2 0 
1.60 â€“ 1.94 35 70 1 1 
1.95 â€“ 2.09 40 80 0 2 
2.10 â€“ 2.34 45 90 3 0 
â‰¥ 2.35 50 100 2 1 
Abbreviations: AM = morning; BSA=body surface area (calculate to 2 decimal places); PM = evening.  
a At a total daily dose of 50 mg, patients should take 1 x 20 -mg tablet in the morning and 2 x 15 -mg tablets in the 
evening. 
If dose modification fails to result in achieving minimal criteria to resume treatment, the 
investigator should discontinue study drug . 
Should the toxicities that re quire dose reduction recur after dose reduction to 20 mg/m2, study 
drug should be discontinued. 
TAS-102 
Protocol No. TO -TAS-102-203 Metastatic Colorectal Cancer  
TO-TAS-102-203 Version 1.0 14 June 2016  Page 41 of 80 [IP_ADDRESS]. Dose Modifications in Response to Non-hematologic Toxicities 
Rules for study drug  dosing modifica tions for treatment- related non -hematologic AEs are 
provided in Table 4. At the discretion of the investigator, patients may continue on study drug at 
the same dose without reduction or interruption for drug- related AEs (irrespective of grade) 
considered unlikely to become serious or life threatening (including, but not limited to, fatigue, 
alopecia, changes in libido, and dry skin).  
Table 4: TAS-102 Dose Modification Criteria for Non-hematologic Toxicities 
Gradea Dose Hold/Resumption  
within a [ADDRESS_17978] occurrence  Suspend treatment until Grade 0 
or 1 Reduce by 1 dose level from the 
previous level  
Fourth occurrence Discontinue treatment  Discontinue treatment  
a Except for  grade 3 nausea and/or vomiting controlled by [CONTACT_19107].  
If there is any uncertainty about continuing therapy or resuming therapy in a patient 
with â‰¥ grade [ADDRESS_17979] be discussed with the Sponsorâ€™s 
medical m onitor before  continuing therapy.  
[IP_ADDRESS]. Dose Modifications in Response to Hematologic Toxicities 
Criteria for dose hold and resumption in response to hematologic toxicities related to 
myelosuppression are described in Table 5 and Table 6, respectively.  
NOTE: For all  patients with decreases in neutrophils and/or platelets, the next cycle of study 
treatment should not be started until the resumption criteria  in Table 6 are met ; these resumption 
criteria apply to the start of the next cycle for all patients regardless of whether or not the hold 
criteria were met.  
TAS-102 
Protocol No. TO -TAS-102-203 Metastatic Colorectal Cancer  
TO-TAS-102-203 Version 1.0 14 June 2016  Page 42 of 80 Table 5: TAS-102 Dose Hold Criteria for Hematologic Toxicities Related to 
Myelosuppression  
Parameter Hold Criteria  
Conventional Units SI Units 
Neutrophils < 500/mm3 < 0.5 Ã— 109/L 
Platelets < 50,000/mm3 < 50 Ã— 109/L 
Abbreviation: SI = Standard International.  
Table 6: TAS-102 Resumption Criteria for Hematologic Toxicities related to 
Myelosuppression  
Parameter Resumption Criteriaa 
Conventional Units SI Units 
Neutrophils â‰¥ 1500/mm3  â‰¥ 1.5 Ã— 109/L 
Platelets â‰¥ 75,000/mm3 â‰¥ 75 Ã— 109/L 
Abbreviation: SI = Standard International.  
a These resumption criteria  apply to the start of the next cycle for all patients regardless of whether or not the hold 
criteria were met.  
Criteria for dose reduction in response to hematologic toxicities are as follows: 
â€¢ Uncomplicated neutropenia or thrombocytopenia â‰¤ g rade 3, do not require a 
reduction in dose of study drug. 
â€¢ Patients who experience uncomplicated g rade 4 neutropenia or thrombocytopenia that 
results in a â‰¤ 1 week delay of the start of the next cycle should start t he next cycle at 
the same dose level.  
â€¢ Patients who experience uncomplicated g rade 4 neutropenia or thrombocytopenia that 
results in a >  1 week delay of the start of the next cycle should start the next cycle at 
one reduced dose level as described in  Table 3. 
Patients who experience complicated â‰¥  grade 3 neutropenia or thrombocytopenia should be 
considered for administration of hematopoietic growth factors, or for a dose reduction in the next 
cycle or both, dependent on the severity of the complication. 
In the event of febrile neutropenia: 
â€¢ Interrupt dos ing until toxicity resolves to g rade 1 or baseline 
â€¢ When resuming dosing, decrease the dose level by 5 mg/m2/dose from the previous 
dose level (as per Table 3). 
[IP_ADDRESS]. TAS-102 Dose Resumption 
If the patient recovers from toxicities requiring dose delay during the 2 -week treatment period of 
a cycle (treatment Days  1 through 5 and Days 8 through 12), and no dose reduction is required, 
study drug may  be resumed during that cycle. If a dose reduction is required, study drug should 
TAS-102 
Protocol No. TO -TAS-102-203 Metastatic Colorectal Cancer  
TO-TAS-102-203 Version 1.0 14 June 2016  Page 43 of 80 be resumed at the start of the next cycle at the appropriate dose level as shown in  Table 3. Do not 
increase the study drug  dose after it has been reduced.  
If the patient recovers fro m toxicities requiring dose delay during the recovery period (Days 13 
through 28), start the next cycle on schedule at the appropriate dose level based 
on Section  [IP_ADDRESS] and Section  [IP_ADDRESS] above. I f the toxicities that are defined above do not 
recover during the treatment or rest period, the s tart of the next cycle can be delayed for a 
maximum of [ADDRESS_17980] study drug discontinued. Discontinuation of both TAS-102 and nivolumab will lead to discontinuation from the study. Future treatment will then be at the discretion of the investigator . 
8.2.5. Nivolumab Treatment Regimen  
The dose of nivolumab is calculated  according to the patientâ€™s weight. All doses of nivolumab 
will be administered to the patient by [CONTACT_19108] 1 and 15 of each cycle. The 
nivolumab should be administered on th e same cycle as the TAS -102. Hence, if there is a delay 
in the TAS-102 dosing, the same delay should be applied to the nivolumab dosing. 
One nivolumab treatment cycle consists of the following: 
â€¢ Day 1: nivolumab (3 mg/kg/dose) intravenous over 60 minutes 
â€¢ Days 2 through 14: rest 
â€¢ Day 15: nivolumab (3 mg/kg/dose) intravenous over 60 minutes 
â€¢ Days 16 through 28: rest 
[IP_ADDRESS]. Nivolumab Preparation and Administration 
Prepare n ivolumab for administration according to the instructions in the package insert .  
8.2.6. Nivolumab Dose Modifications 
Recommendations for nivolumab dose modifications are listed in Table 7 . For patients who 
experience mild or moderate infusion reactions, the infusion should either be interrupted or the 
rate should be slowed. If a patient has a severe or life-threatening infusion reaction, the 
nivolumab should be discontinued. Discontinuation of both TAS-102 and nivolumab will lead to discontinuation from the study. Future treatment will then be at the discretion of the investigator . 
 
TAS-102 
Protocol No. TO -TAS-102-203 Metastatic Colorectal Cancer  
TO-TAS-102-203 Version 1.0 14 June 2016  Page 44 of 80 Table 7: Recommended Dose Modifications for Nivolumab 
Adverse Reaction  Severitya Dose Modification  
Colitis Grade 2 or grade 3 diarrhea  or 
colitis Withhold doseb 
Grade 4 diarrhea or colitis  Permanently discontinue 
Pneumonitis Grade 2 pneumonitis  Withhold doseb 
Grade 3 or grade 4 pneumonitis Permanently discontinue 
Hepatitis Aspartate aminotransferase 
(AST) or alanine aminotransferase (ALT) more 
than 3 and up to 5 Ã— the upper 
limit of normal (ULN) or total 
bilirubin more than 1.5 and up to 
3 Ã— the ULN  Withhold dose
b 
AST or ALT more than 5 Ã— the ULN or total bilirubin more than 
3 Ã— the ULN  Permanently discontinue 
Hypophysitis Grade 2 or grade 3 hypophysitis  Withhold doseb 
Grade 4 hypophysitis  Permanently discontinue 
Adrenal Insufficiency Grade 2 adrenal insufficiency  Withhold doseb 
Grade 3 or grade 4 renal insufficiency  Permanently discontinue 
Type 1 Diabetes Grade 3 hyperglycemia Withhold doseb 
Grade 4 hyperglycemia Permanently discontinue 
Nephritis and Renal D ysfunction Serum creatinine more than 1.5 
and up to 6 Ã— the ULN  Withhold doseb 
Serum creatinine more than 6 Ã— the ULN Permanently discontinue 
Rash Grade [ADDRESS_17981] occurrence  Withhold dose
b 
Recurrence of same grade 3 adverse reaction  Permanently discontinue 
TAS-102 
Protocol No. TO -TAS-102-203 Metastatic Colorectal Cancer  
TO-TAS-102-203 Version 1.0 14 June 2016  Page 45 of 80 Adverse Reaction  Severitya Dose Modification  
Life threatening or grade 4 
adverse reaction  Permanently discontinue 
Requirement for 10 mg per day or greater prednisone or 
equivalent for more than 12 weeks  Permanently discontinue 
Persistent grade 2 or grade 3 adverse reactions lasting 
12 weeks or longer  Permanently discontinue 
a Toxicity was graded per the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0. 
b Resume treatment when the adverse reaction returns to grade 0 or 1.  
8.3. Treatment Compliance  
Compliance to all study drug administration should be documented in the patientâ€™s source 
documents. 
8.4. Study Drug Accountability  
In accordance with International Council for Harmonisation of Technical Requirements for 
Registration of Pharmaceuticals for Human Use (ICH) and  local regulatory requirements, the 
investigator and/or the person responsible for dispensing investigational drug must be able at all 
times to account for all investigational product provided to the site.  
Dose reductions, interruptions, and reason for these actions must be recorded in the patientâ€™s 
source documents. 
All used and unused study drug shipped to the investigator must be returned to the Sponsor or its 
representative. If on -site destruction is required by [CONTACT_19109], such requirements must be 
documented in the institutionâ€™s Standard Operating Procedure and provided to the Sponsor or its 
representative for review.  
No study drugs are to be used outside of this study. 
9. STUDY ASSESSMENTS  
The study assessments are described by [CONTACT_19110]. All information required by [CONTACT_19111]. 
The study schedule must be followed; however, in unavoidable circumstances, (eg, holidays, 
weekends) a window of Â± 3 days is allowable for study procedures, as long as the proper order of 
procedures and assessments is maintained. A window of Â± [ADDRESS_17982] scans, and 
follow-up visits. These windows are not applicable during the Baseline Period (up to 28 days before enrollment). If any baseline assessments are repeated on Day [ADDRESS_17983] 
ensure the patient meets the eligibility criteria listed in Section 7.3.1 and Section  7.3.2. 
7$6
3URWRFRO1R727$6 0HWDVWDWLF&RORUHFWDO&DQFHU
727$69HUVLRQ-XQH  3DJH RI$IWHUFRQILUPDWLRQRIHOLJLELOLW \SDWLHQWVVKRXOGUHFHLYHWKH ILUVWGRVHRIVWXG\WUHDWPHQW'D\
RI&\FOHZLWKLQFDOHQGDUGD \VDIWHUHQUROOPHQW7KHPD[LPX PVFUHHQLQJSHULRGLVGD\V
HOLJLEOHSDWLHQWVPX VWEHHQUROOHGE\'D\RIVFUHHQLQJ
(QUROOHGSDWLHQWVZLOO EHDVVLJQHGDXQLTXH GLJLWSDWLHQWQXP EHU
$OO6WXG\3URFHGXUHV
,QIRUPHG&RQVHQW
$VLJQHGDQGGDWHG,&)ZLOOEHREW DLQHGIURPWKHSDWLHQWDVUHT XLUHGE\WKHSURWRFROEHIRUHDQ\
EDVHOLQHSURFHGXUHVD UHFRQGXFWHG$VLJQHGF RS\RIWKH,&)ZLO OEHJLYHQWRWKHSDWLHQW
0HGLFDO+LVWRU\
$FRPSOHWHPHGLFDOKLVWRU\Z LOOEHREWDLQHGGXULQJEDVHOLQHZLW KLQGD\VEHIRUHWKHILUVWVWXG\
GUXJDGPLQLVWUDWLRQRQ'D\&\FOH
7KHSDWLHQWÂ¶VPHGLFDOKLVWRU\ VKRXOGEHUHFRUGHGRQWKH0HGLFDO +LVWRU\VHFWLRQRIWKHH&5)
([LVWLQJVLJQVDQGV\PSWRPVZLOOEHREWDLQHGZLWKLQGD\VEHIR UHVWXG\GUXJDGPLQLVWUDWLRQRQ
'D\&\FOH
+LVWRORJLF&RQILUPDWLRQ
&RQILUPDWLRQRI066UHIUDFWRU\P&5&YLDDSDWKRORJ\UHSRUWVKRX OGEHREWDLQHGD WEDVHOLQH
ZLWKLQGD\VEHIRUHDGPLQLVWUD WLRQRIWKHILUVWGRVHRIVWXG\ GUXJRQ'D\&\FOHSDWKRORJ\
PD\EHIURPSULPDU\WXPRURUPHW DVWDVLV7KHSDWKRORJ\UHSRUW VKRXOGEHDYDLODEOHLQWKH
SDWLHQWÂ¶VVRXUFHGRFXPHQWV
CCI
TAS-102 
Protocol No. TO -TAS-102-203 Metastatic Colorectal Cancer  
TO-TAS-102-203 Version 1.0 14 June 2016  Page 47 of 80 9.1.6. Physical Examination 
A complete physical examination will be performed at the time points  listed below: 
â€¢ Within 7 days before study drug administration on Day 1 of Cycle 1 
â€¢ Beginning with Cycle 2, obtain within 24 hours before the start of study treatment on 
Day 1 of every cycle  
â€¢ End of Treatment visit (if applicable)  
â€¢ 30-day Safety Follow-up visit 
9.1.7. Baseline Signs and Symptoms  
Signs and symptoms present after signature [CONTACT_19139] 7 days before study treatment on Day 1 of Cycle 1 should be recorded in the patientâ€™s source documents. 
â€¢ Height, Vital Sign Measurements, and Weight  
â€¢ The patientâ€™s  height will be obtained only during baseline before study drug 
administration within 7 days before Day 1 of Cycle 1.  The patientâ€™s vital sign 
measurements (blood pressure, heart rate, body temperature, and respi[INVESTIGATOR_1487]) will be collected at the time p oints listed below. All the vital sign measurements are to be 
obtained with the patient in a position that is consistent for all time points for each 
patient. 
â€¢ Beginning with Cycle 2, obtain within 24 hours before the star t of study drug 
administration on Day 1 of every cycle  
â€¢ End of Treatment visit (if applicable)  
â€¢ 30-day Safety Follow-up visit 
â€¢ Weight will be collected within 7 days of Day 1 Cycle 1 , Cycle 1 Day 15, Day 1 and 
Day 15 of all subsequent cycles, End of Treatment visit, and at the 30- day Safety 
Follow-up visit.  
9.1.8. Performance Status  
An ECOG performance status  score  will be 
obtained at the following time points: 
â€¢ Within 28 days before study drug administration on Day 1 of Cycle  1 
â€¢ Obtain within 24 hours before the start of study drug administration on Day 1 in 
every cycle  and Day 15 
â€¢ End of Treatment visit (if applicable)  
â€¢ 30-day Safety Follow-up visit 
9.1.9. Clinical Laboratory Evaluations 
Samples for hematology, serum chemistry and urinalysis assessments will be collected and 
measured as described in Section [IP_ADDRESS], Section  [IP_ADDRESS], and Section  [IP_ADDRESS]. Laboratory 
assessments obtained before the signing of the ICF may be used as screening laboratory values if 

TAS-[ADDRESS_17984] be followed and reported as required by [CONTACT_760] ( see Section 11.1, 
Adverse Events/Serious Adverse Events and Section  11.2, Laboratory Evaluations) . In addition, 
follow the criteria for repeat testing listed in Section 11.2.2 as needed.  
[IP_ADDRESS]. Hematology 
Blood samples for hematology assessments will be obtained at the following time points and when clinically indicated:  
â€¢ Within 7 days before  Day 1 of Cycle 1  (Laboratory results obtained before signing 
the ICF may be used if the results were obtained within  7 days before Day  1 of 
Cycle 1.) 
â€¢ Day 15 of each cycle  
â€¢ Beginning with Cycle 2, obtain blood samples within 24 hours before the start of study drug administration on Day 1 of every cycle 
â€¢ End of Treatment visit (if applicable)  
â€¢ 30-day Safety Follow-up visit 
In addition, the criteria for repeat testing listed in Section 11.2.2, will be followed as needed. 
Hematology parameters that will be measured are li sted in Table 8. 
TAS-102 
Protocol No. TO -TAS-102-203 Metastatic Colorectal Cancer  
TO-TAS-102-203 Version 1.0 14 June 2016  Page 49 of 80 Table 8: Hematology Laboratory Parameters 
Hemoglobin  White blood cell ( WBC) count with 
differential (automated): 
Hematocrit  Neutrophils 
Platelets Lymphocytes 
Red blood cell count Monocytes 
 Eosinophils 
 Basophils 
[IP_ADDRESS]. Serum Chemistry  
Blood will be collected at the following time points for serum chemistry assessments: 
â€¢ Within 7 days prior to Day 1 of Cycle 1 (L aboratory results obtained before  signing 
the ICF may be used if the results were obtained within 7 days before  Day 1 of 
Cycle 1.) 
â€¢ Day 15 of each cycle  
â€¢ For all subsequent cycles, obtain within 24 hours before the start of s tudy drug 
administration on Day 1 of every cycle 
â€¢ End of Treatment Visit (if applicable)  
â€¢ 30-day Safety Follow- up Visit. 
In addition, follow the criteria for repeat testing listed in Section 11.2.2 as needed.  
Table 9 lists the serum chemistry parameters that will be measured.  
Table 9: Serum Chemistry Laboratory Parameters  
ALT  Creatinine  Chloride 
AST  Blood urea nitrogen Calcium 
Alkaline phosphatase  Sodium Albumin 
Bilirubina Potassium Glucose 
Thyroid stimulating hormone Thyroxine 4 (T4)   
Abbreviations: ALT = alanine aminotransferase; AST = aspartate aminotransferase.  
a In case of elevation in total bilirubin, fractionation (direct/indirect) should be performed.  
[IP_ADDRESS]. Urinalysis  
Collect urine samples for qualitative (dipstick) analysis, to include tests for protein,  glucose, 
urobilinogen, red blood cell count, and white blood cell count , at the time points listed below:  
â€¢ Within 7 days before Day 1 of Cycle 1  (Laboratory results obtained before signing 
the ICF may be used if the results were obtained within 7 days befo re Day 1 of 
Cycle 1.) 
TAS-102 
Protocol No. TO -TAS-102-203 Metastatic Colorectal Cancer  
TO-TAS-102-203 Version 1.0 14 June 2016  Page 50 of 80 â€¢ As clinically indicated thereafter  
If a new abnormality is identified, quantitative u rinalysis should be performed. 
In addition, follow the criteria for repeat testing listed in Section 11.2.[ADDRESS_17985] results should be recorded in the patientâ€™s source documents (Note: More frequent pregnancy assessments should be performed if required by [CONTACT_1769]):  
â€¢ Within 7 days prior to Day 1 of Cycle 1 
â€¢ End of Treatment or 30-day Safety Follow -up Visit 
Female patients who are considered not to be of child bearing potential must have a history of being post-menopausal (no menses for 12 consecutive months without an alternative medical 
cause), or hysterectomy that is clearly documented in the patientâ€™s source documents. 
9.1.11. Tumor Measurements  
Tumor assessments/contrast -enhanced CT scans of the chest and abdomen (and pelvis, if 
clinically indicated) must be obtained at each time point listed below for all patients:  
â€¢ Within 28 days before Day 1 of Cycle 1 . Scans obtained before the patient signs the 
ICF may be used if the date of the scan is within 28 days of enrollment. 
â€¢ Every 2 cycles during study treatment  
â€¢ For patients who discontinue treatment because of radiologic disease progression  by 
[CONTACT_19104], an additional tumor assessment is not required at the End of Treatment visit.  
â€¢ For patients who discontinued treatment for reasons other than radiologic disease progression by [CONTACT_19104] , every effort should be made to perform an end of treatment 
tumor assessment before the star t of new anticancer therapy and should be followed 
for tumor response every 2 cycles  until the patient develops radiologic disease 
progression (or death) or initiation of new anticancer therapy (whichever occurs first).  
On-site tumor assessments will be performed by [CONTACT_19112]. Results of these assessments including response for target and non-target lesions and appearance of new lesions will be th e basis for the continuation or 
discontinuation of study drug. Response definitions are provided in Section  10.3.1.  
Patients with tumor progression determined by [CONTACT_19113] 
6-month evaluation but without rapid clinical deterioration or change in performance status  who 
do not require additional immediate therapy, may continue to be treated with and clinically 
observed after the assigned imaging schedule to allow detection of a subsequent tumor response. 
Symptoms of clinical progression must be documented in the patientâ€™s source documents and 
must be reported as AEs. Every effort should be made to document objective progr ession even 
after discontinuation of treatment.  
TAS-[ADDRESS_17986] be used to characterize each 
identified and reported lesion at baseline, throughout the study, and during the follow-up period. 
All patientsâ€™ files an d radiological assessments must be available for source verification and may 
be submitted for extramural review for initial assessment of antitumor activity.  
Results of any unscheduled evaluations should be recorded in the patientâ€™s source documents. 
9.1.12. Prior and Concomitant Medications 
All therapi[INVESTIGATOR_19080], prescription and over-the- counter, will be collected from the time 
the ICF is signed through the 30- day Safety Follow -Up visit, including any medication used to 
treat AEs or SAEs during the S afety Follow-up Period. Use of concomitant medication should be 
documented in the patientâ€™s source documents.  
The time of initiation of new anticancer therapy received during the [ADDRESS_17987] medical events (AEs or SAEs) from the time of 
signed informed consent through [ADDRESS_17988] dose of study drug  or until the sta rt of new 
antitumor therapy, whichever is earlier . 
Serious AEs should be reported to Taiho Oncology, Incorporated (TOI) Pharmacovigilance or its 
designee. If serious medical occurrences or deaths outside the 30-day follow-up period are 
reported to or observed by [CONTACT_941] i nvestigator that he/she believes are related to the administration 
of the study drug , it is the investigatorâ€™s responsibility to re port this occurrence to TOI 
Pharmacovigilance or its designee. See Section 11.1.1 and Section  11.1.2, respectively,  for 
definitions and detailed reporting of AEs and SAEs.  
9.2. Assessments by [CONTACT_19114] 9.1 for details about specific assessments.  
9.2.1. Baseline Procedures Before Enrollment  
[IP_ADDRESS]. Day âˆ’28 through Day âˆ’1 
â€¢ Signature [CONTACT_4007] I CF 
â€¢ Review of inclusion and exclusion criteria 
â€¢ Medical history  
â€¢ Histological confirmation of mCRC from either the primary or metastatic site of 
disease 
â€¢ ECOG performance status  
â€¢ Tumor measurement (by [CONTACT_3610])  
â€¢ Concomitant medication  
7$6
3URWRFRO1R727$6 0HWDVWDWLF&RORUHFWDO&DQFHU
727$69HUVLRQ-XQH  3DJH RIx7XPRUELRSVLHVIURPIUHVKWLVVXHZLWKLQGD\VRI&\FOH'D\ 
x$(6$(DVVHVVPHQW
'D\Ã­WKURXJK'D\Ã­
x5HYLHZRILQFOXVLRQDQG H[FOXVLRQFULWHULD
x3K\VLFDOH[DPLQDWLRQ
x%DVHOLQHVLJQVDQGV\PSWRPV
x+HLJKW
x9LWDOVLJQPHDVXUHPHQWVEOR RGSUHVVXUHKHDUWUDWHERG\WHPSH UDWXUH
UHVSLUDWLRQUDWHDQGERG\ZHLJKW DQGFDOFXODWHWKHSDWLHQWÂ¶V% 6$
x%ORRGVDPSOHVIRUKHPDWRORJ\DQGVHUXPFKHPLVWU\
x8ULQHVDPSOHIRUXULQDO\VLV
x3UHJQDQF\WHVW
x&RQFRPLWDQWPHGLFDWLRQ
x$(6$(DVVHVVPHQW
2Q7UHDWPHQW3HULRG
&\FOH'D\
6WXG\WUHDWPHQWVKRXOGEHVWDUWH GZLWKLQFDOHQGDUGD\VDIWHU WKHSDWLHQWKDVEHH QHQUROOHGLQWKH
VWXG\7KHIROORZL QJZLOOEHDVVHVVHG
x5HYLHZRILQFOXVLRQDQG H[FOXVLRQFULWHULD
x(&2*SHUIRUPDQFHVWDWXVF RQILUPDWLRQRIHOLJLELOLW\
x$GPLQLVWHULQWUDYHQRXVQLYROXPDE
x'LVSHQVHVWXG\GUXJ7$6
x&RQFRPLWDQWPHGLFDWLRQ
x$(6$(DVVHVVPHQW
&\FOH'D\
x%ORRGVDPSOHVIRUKHPDWRORJ\DQGVHUXPFKHPLVWU\
x2EWDLQWKHSDWLHQWÂ¶VZHLJKW
x(&2*SHUIRUPDQFHVWDWXV
x$GPLQLVWHULQWUDYHQRXVQLYROXPDE
x&RQFRPLWDQWPHGLFDWLRQCCI
7$6
3URWRFRO1R727$6 0HWDVWDWLF&RORUHFWDO&DQFHU
727$69HUVLRQ-XQH  3DJH RIx$(6$(DVVHVVPHQW
6XEVHTXHQW&\FOHV&\FOH;'D\
2EWDLQZLWKLQKRXUVEHIRUH'D\ VWXG\GUXJDGPLQLVWUDWLRQ %HIRUHVWDUWLQJVXEVHTXHQW
F\FOHVYHULI\WKDWSDWLHQWVZLW KWR[LFLWLHVKDYHPHWUHVXPSWLR QFULWHULDEHIRUHDGPLQLVWHULQJ
VWXG\GUXJ
x3K\VLFDOH[DPLQDWLRQ
x9LWDOVLJQPHDVXUHPHQWVEORRGSU HVVXUHKHDUWUDWHERG\WHPSH UDWXUH
UHVSLUDWLRQUDWHDQGERG\ZHLJKW
x(&2*SHUIRUPDQFHVWDWXV
x%ORRGVDPSOHVIRUKHPDWRORJ\DQGVHUXPFKHPLVWU\
x$GPLQLVWHULQWUDYHQRXVQLYROXPDE
x'LVSHQVHVWXG\GUXJ7$6
x&RQFRPLWDQWPHGLFDWLRQ
x$(6$(DVVHVVPHQW
6XEVHTXHQW&\FOHVÂ±&\FOH;'D\
x%ORRGVDPSOHIRUKHPDWRORJ\DQGFKHPLVWU\
x%RG\ZHLJKW
x(&2*SHUIRUPDQFHVWDWXV
x$GPLQLVWHULQWUDYHQRXVQLYROXPDE
x&RQFRPLWDQWPHGLFDWLRQ
x$(6$(DVVHVVPHQW
(YHU\F\FOHVIURP6WDUWRI7UHDWPHQW
x7XPRUPHDVXUHPHQWDVVHVVPHQW&7VFDQCCI
CCI
CCI
7$6
3URWRFRO1R727$6 0HWDVWDWLF&RORUHFWDO&DQFHU
727$69HUVLRQ-XQH  3DJH RI(QGRI7UHDWPHQW9LVLW
,IWKHGHFLVLRQWRGLVFRQWLQXHVWX G\GUXJVLVPDGHZLWKLQZHH NVDIWHUWKHSDWLHQWÂ¶VODVW
WUHDWPHQWYLVLWDQ(QGRI 7UHDWPHQW9LVLWLV QRWUHTXLUHG XQOHVVGHHPHGFOLQLFDOO\QHFHVVDU\E\
WKHLQYHVWLJDWRU,IWKHGHFLVLRQWRGLVFRQWLQXHVWXG\GUXJVE HFDXVHRISURYHQUDGLRORJLFGLVHDVH
SURJUHVVLRQRURWKHUUHDVRQVLVP DGHPRUHWKDQZHHNVDIWHUW KHODVWWUHDWPHQWYLVLWDQ(QGRI
7UHDWPHQWYLVLWLVUHTXLUHG,I WKLVYLVLWRFFXUVZLWKLQZHHN VRIWKHGD\6DIHW\)ROORZXS
YLVLWWKHYLVLWVFDQEHFRPEL QHGDQGWKHLQIRUPDWLRQDWWKH (QGRI7UHDWPHQWYLVLWZLOOEH
HQWHUHGLQWRWKHGD\6D IHW\)ROORZXSYLVLW
3HUIRUPWKHIROORZLQJDVVHVVPHQWV
x3K\VLFDOH[DPLQDWLRQ
x9LWDOVLJQPHDVXUHPHQWVEORRGSU HVVXUHKHDUWUDWHERG\WHPSH UDWXUH
UHVSLUDWLRQUDWHDQGERG\ZHLJKW
x(&2*SHUIRUPDQFHVWDWXV
x7XPRUPHDVXUHPHQWDVVHVVPHQW&7VFDQ
x%ORRGVDPSOHVIRUFKHPLVWU\DQGKHPDWRORJ\

x3UHJQDQF\WHVW
x)RUSDWLHQWVZKRGLVFRQWLQXHWUHD WPHQWIRUUDGLRORJLFGLVHDVHS URJUHVVLRQHYHU\
HIIRUWVKRXOGEHPDGHWRSHUIRUP DQHQGRIWUHDWPHQWWXPRUDVVH VVPHQWEHIRUH
WKHVWDUWRIQHZDQWLFDQFHUWKHUD S\3DWLHQWVWKDWGLVFRQWLQXHG WUHDWPHQWIRU
UHDVRQVRWKHUWKDQGLVHDVHSU RJUHVVLRQVKRXOGFRQWLQXHWREHIR OORZHGIRUWXPRU
UHVSRQVHHYHU\F\FOHVXQWLOWKH SDWLHQWGHYHORSVUDGLRORJLFG LVHDVHSURJUHVVLRQ
RUGHDWKRULQLWLDWLRQRIQHZDQ WLFDQFHUWKHUDS\ZKLFKHYHUR FFXUVILUVW
x&RQFRPLWDQWPHGLFDWLRQLQFOXGLQJ DQ\QHZDQWLFDQFHUWKHUDS\DQ GWLPHRI
LQLWLDWLRQ
x$(6$(DVVHVVPHQW
'D\6DIHW\)ROORZXS9LVLW
$6DIHW\)ROORZXSYLVLWZLOO EHFRQGXFWHGGD\VD IWHUWKHSDWLHQWÂ¶VODVWGRVHRIVWXG\GUXJ,I
WKHSDWLHQWZLOOEHVWD UWLQJQHZDQWLFDQFHUWKHUDS\ZLWKLQWKH GD\ZLQGRZDIWHUWKHODVWGRVH
RIVWXG\GUXJWKHGD\6DIH W\)ROORZXSYLVLWVKRXOGEHSHUI RUPHGEHIRUHWKHVWDUWRIQHZ
DQWLFDQFHUWKHUDS\,IWKHSDWLH QWLVXQDEOHWRUHWXUQWRWKHV LWHEHIRUHWKHL QLWLDWLRQRIQHZ
WUHDWPHQWDIROORZ XSSKRQHFDOOFDQEHFRQGXFWHGE\WKHVLWH WRFROOHFWDQ\QHZVDIHW\
LQIRUPDWLRQWKDWRFFXUUHGEHWZHH QWKHHQGRIVWXG\WUHDWPHQWDQ GWKHLQLWLDWLRQRIWKHQHZ
WUHDWPHQW
3HUIRUPWKHIROORZLQJDVVHVVPHQWV
x3K\VLFDOH[DPLQDWLRQCCI
TAS-102 
Protocol No. TO -TAS-102-203 Metastatic Colorectal Cancer  
TO-TAS-102-203 Version 1.0 14 June 2016  Page 55 of 80 â€¢ Vital sign  measurement s (blood pressure, heart rate, body temperature, 
respi[INVESTIGATOR_1487]) and body weight 
â€¢ ECOG performance status  
â€¢ Blood samples for chemistry and hematology  
â€¢ Pregnancy test   
â€¢ Concomitant medication, including any new anticancer therapy and time of 
initiation 
â€¢ AE/SAE assessment  
9.2.5. Survival Follow- up after 30 -Day Safety Visit 
The following assessments should be obtained at scheduled  8-week time intervals during the 
survival follow-up period (these may be telephonic): 
â€¢ Tumor measurement (by [CONTACT_3610], see Section 10) every 2 cycles until 
radiologic disease progression (for patients who discontinued treatment for 
reasons other than disease progression) or initiation of new anticancer therapy 
(whichever occurs first)  
â€¢ Concomitant medications â€“ collect antitumor therapi[INVESTIGATOR_19081]  
â€¢ Contact [CONTACT_4676]/caregiver to determine survival status (alive/dead)  
â€¢ SAE collection only if the SA E is related to study drug 
Patients will be followed for survival until the study discontinuation criteria are met. The  
investigators will be informed when these criteria  are reached. 
TAS-102 
Protocol No. TO -TAS-102-203 Metastatic Colorectal Cancer  
TO-TAS-102-203 Version 1.0 14 June 2016  Page 56 of 80 10. EFFICACY ASSESSMENT CRITERIA 
The determination of antitumor efficacy will be based on objective tumor assessments made by 
[CONTACT_093]/local radiologist according to the irRC13 and revised RECIST criteria of 
unidimensional evaluation.[ADDRESS_17989] and  enhanced magnetic resonance 
imaging (MRI ) of the abdomen (and pelvis if clinically indicated). A s pi[INVESTIGATOR_19082] a [ADDRESS_17990] and abdomen (and pelvis if clinically indicated or obtained at baseline) at each time 
point. Only CT and MRI may be used for tumor measurement. 
Clinical lesions will only be considered measurable when they are superficial (eg,  skin nodules, 
palpable lymph nodes). In the case of skin lesions, documentation by [CONTACT_6775], 
including a ruler to estimate the size of the lesion, is recommended. 
Ultrasound should not be used to measure tumor lesions that are clinically not easi ly accessible 
for objective response evaluation (eg, visceral lesions). Ultrasound is a possible alternative to 
clinical measurements of superficial palpable nodes, subcutaneous lesions, and thyroid nodules. Ultrasound might also be useful to confirm the c omplete disappearance of superficial lesions 
usually assessed by [CONTACT_12148].  
An additional fluorodeoxyglucose positron emission tomography (FDG- PET) scan may help 
confirm the diagnosis of suspi[INVESTIGATOR_19083]. A â€œpositiveâ€ FDG- PET scan lesion 
is one that is FDG avid â€œwith an uptake greater than twice that of the surrounding tissue on the attenuation corrected image.â€ However, this scan is not mandatory. A FDG- PET scan alone 
cannot replace a MRI or contrast -enhanced CT.  
10.2. Immune-related Response Criteria  
10.2.1. Immune-related Response Criteria Definitions  
Measureable Disease: Neoplastic masses that can be precisely measured in [ADDRESS_17991] be â‰¥ [ADDRESS_17992] be â‰¥ [ADDRESS_17993] be â‰¥ [ADDRESS_17994] perpendicular.  
Non-measurable disease: Non -measurable disease s are those that are not suitable for quantitative 
assessment over time. These include:  
â€¢ Neoplastic masses that are too small to measure, because their longest uninterrupted 
diameter or longest perpendicular are < 10 mm. 
â€¢ Neoplastic masses whose boundaries cannot be distinguished. This includes masses 
that cannot be demarcated from surrounding tissue because of inadequate contrast, 
masses with overly complex morphology, or those with highly heterogeneous tissue composition. 
â€¢ Other types of lesions that are conf idently felt to represent neoplastic tissue, but 
difficult to quantify in a reproducible manner. These include bone metastases, leptomeningeal metastases, malignant ascites, pleural/pericardial effusions, 
inflammatory breast disease, lymphangitis cutis/pulmonis cystic lesions, ill-defined 
abdominal masses , etc. 
For irRC, only index lesions selected at baseline and measurable new lesions are taken into 
account.  
10.2.2. Immune-related Response Criteria  
At the baseline tumor assessment, the sum of the products of the [ADDRESS_17995] perpendicular 
diameters ( SPD) of all index lesions (5 lesions per organ, up to 10 visceral lesions and 
5 cutaneous index lesions) is calculated.  
At each subsequent tumor assessment, the SPD of the index lesions and of new, measurable lesions (â‰¥ 5 Ã— 5 mm; up to 5 new lesions per organ: 5 new cutaneous lesions and 10 visceral 
lesions) are added together to provide the total time -point tumor burden: 
Tumor burden = SPD
index lesions + SPD new, measureable lesions  
Overall responses using irRC are defined as follows and presented in Table 10: 
â€¢ Complete Response (immune- related CR [irCR] ): Complete disappearance of all 
tumor lesions (whether measurable or not, and no new lesions). Complete response 
must be confirmed by [CONTACT_491], consecutive assessments made no less than [ADDRESS_17996] documented. 
â€¢ Partial Response (immune -related PR [irPR]): Decrease in SPD of 50% or greater by 
a consecutive assessment at least [ADDRESS_17997] documentation.  
â€¢ Stable Disease (immune -related SD [irSD]): Failure to meet criteria for irCR or irPR, 
in absence of progressive disease (irPD).  
â€¢ Progressive Disease ( immune-related PD [ irPD]): At least 25% increase in S PD 
relative to nadir (minimum recorded tumor burden). Confirmation by a repeat, 
consecutive assess no less than [ADDRESS_17998] documented. 
TAS-102 
Protocol No. TO -TAS-102-203 Metastatic Colorectal Cancer  
TO-TAS-102-203 Version 1.0 14 June 2016  Page 58 of 80 Table 10: Derivation of irRC Overall Responses13  
Measurable Response  Non-measurable Response Overall Response  
Index and New, 
Measurable Lesions (Tumor Burden)  %
a Non-index Lesions  New, Non -measurable 
Lesions Using irRC 
â†“ 100 Absent Absent irCRb 
â†“ 100 Stable Any irPRb 
â†“ 100 Unequivocal 
progression Any irPRb 
â†“ â‰¥ 50 Absent/stable  Any irPRb 
â†“ â‰¥ 50 Unequivocal 
progression Any irPRb 
â†“ < 50 to <  25 â†‘ Absent/stable  Any irSDb 
â†“ < 50 to <  25 â†‘ Unequivocal progression Any irSD
b 
â‰¥ 25 â†‘ Any Any irPDb 
Abbreviations: irCR = immune -related complete response; irPD = immune -related progressive disease; irPR = 
immune-related partial response; irRC = immune -related response criteria; irSD = immune -related stable disease.  
Note: Complete response and partial response must be confirmed by [CONTACT_491], consecutive assessments made no less 
than [ADDRESS_17999] documented .  
a Assuming response (irCR and irPR) and progression (irPD) are confirmed by a second, consecutive assessment at 
least 4 weeks apart.  
b Decreases assessed relative to baseline, including measurable lesions only (> 5 Ã— 5 mm). 
If a patient is classified as having irPD at a postbaseline tumor assessment, then c onfirmation of 
irPD by a second scan in the absence of rapid clinical deterioration is required. The definition of 
confirmation of progression represents an increase in tumor burden â‰¥ 25% compared with the 
nadir at [ADDRESS_18000] 4 week s apart. It is recommended that this be done at 
the discretion of the investigator because follow-up with observation alone may not be 
appropriate for patients with a rapid decline in performance irRC ( Table 10), as most of these 
late responding patients have a trend toward response within [ADDRESS_18001] Tumor Definitions   
Measurable L esions: 
â€¢ Measurable visceral lesions: Lesions that can be accurately measured in at least [ADDRESS_18002] diameter (to be recorded) â‰¥ [ADDRESS_18003] or MRI 
scan if the slice thickness is > 5 mm.  
TAS-102 
Protocol No. TO -TAS-102-203 Metastatic Colorectal Cancer  
TO-TAS-102-203 Version 1.0 14 June 2016  Page 59 of 80 â€¢ Measurable pathological lymph nodes: A malignant lymph node must be considered 
pathologically enlarged with high suspi[INVESTIGATOR_19084] â‰¥ [ADDRESS_18004] 
linear dimension perpendicular to the nodeâ€™s longest diameter as assessed within the same plane that the scan was acquired.  
Only measurable lesions can be selected as target lesions.  
Non-measurable Lesions
: Non-measurable lesions incl ude: 
â€¢ Small visceral metastatic lesions that have a longest dimension less than 10 mm or if 
slice thickness is greater than 5 mm less than twice the slice thickness.  
â€¢ Abnormal and suspected metastatic lymph nodes that are â‰¥ 10 mm to < 15 mm in the 
short axis. 
â€¢ Truly non- measurable lesions (eg, ascites and peritoneal carcinomatosis).  
All non-measurable lesions can only be selected as non -target lesions.  
Target Lesions : 
â€¢ All measurable lesions up to a maximum of 2 lesions per organ and 5 lesions in total, representative of all involved organs/tissues should be identified as target lesions. 
â€¢ Target lesions should be selected on the basis of their size (visceral lesion with the 
longest diameter and lymph node with the measurement of short axis), be 
representative of  all involved organs/tissues, but in addition should be those that lend 
themselves to reproducible repeated measurements.  
â€¢ When recording tumor measurements, the longest diameter will be measured for each non-nodal target lesion. For measurable pathological  lymph nodes that may be 
identified as target lesions, the short axis measurement will be combined with the 
measurements of non-nodal (ie, visceral lesion) target lesions. Therefore, in cases of 
CR when abnormal nodes have been used as target lesions, the sum of diameters will not reduce to a null value. Target lesions will be followed and measured at each 
subsequent time point. 
The sum of the diameters for all target lesions will be calculated and recorded. The baseline sum 
will be used as a reference to further characterize any objective tumor assessment in the 
measurable dimension of the disease.  
â€¢ Assign a measurement to all target lesions regardless of size. An option of â€œtoo small 
to measureâ€ will be provided if a measurement cannot be assigned. A value of zero 
should only be assigned in the case of a CR. 
â€¢ An option of â€œNot Assessableâ€ for a lesion will only apply to lesions that cannot be read due to technical reasons, for example:  
1. CT artifact.  
2. Patient positioning where the lesions are obstructed or cannot be seen.  
3. Lesions that may not be seen in their entirety because of CT slice thickness.  
TAS-102 
Protocol No. TO -TAS-102-203 Metastatic Colorectal Cancer  
TO-TAS-102-203 Version 1.0 14 June 2016  Page 60 of 80 â€¢ In cases where a lesion divides into [ADDRESS_18005] diameters of the fragmented 
portions should be added together to calculate the target lesion sum.  
â€¢ In cases where [ADDRESS_18006] diameter for the 
â€œcoalesced lesionâ€. 
Non-target Lesions : 
â€¢ Non-target lesions include all non -measurable lesions and measurable lesions that 
have not been selected as target lesions  
â€¢ Lymph nodes that have a short axis < 10 mm are considered non-pathological and should not be recorded. 
â€¢ Any equivocal lesion without clear diagnosis (eg, uncharacteristic solitary lung 
nodule without biopsy, uncharacteristic thyroid mass lesion without fine needle 
aspi[INVESTIGATOR_1516] ) may be considered a non- target lesion if it cannot be differentiated from a 
benign lesion.  
â€¢ All other lesions (or sites of disease), including pathological lymph nodes, should be identified as non-target lesions and should also be recorded at Baseline. 
Measurements are not required, but their presence, absence, or unequivocal progression should be followed throughout the study. 
It is possible to record multiple non-target lesions involving the same organ as a single item on the eCRF (eg, multiple enlarged  pelvic lymph nodes or multiple liver metastasis).  
10.3.2. RECIST Response Criteria  
On-site assessments will include the assessment of: 
â€¢ Target and non-target tumor responses. 
â€¢ Overall response.  
The above assessments will be made as per the time points identified in  Section 9.1.11.  
[IP_ADDRESS]. RECIST Target and Non- target Response Assessments  
[IP_ADDRESS].1. RECIST Criteria for Assessment of Tumor Response  
Assessments will be made based on the following definitions
14: 
TAS-102 
Protocol No. TO -TAS-102-203 Metastatic Colorectal Cancer  
TO-TAS-102-203 Version 1.0 14 June 2016  Page 61 of 80 TARGET LESIONS  
Lesions Response:  Definition:  
Complete Response (CR)  The disappearance of all target lesions. Any pathological lymph nodes must 
have reduction in short axis to <  10 mm. 
Partial Response (PR)  At least a 30% decrease in the sum of diameters of the target lesions, taking as a reference the baseline sum diameters.  
Progressive Disease (PD)  At least a 20% increase in the sum of diameters of the target lesions, taking as a reference the smallest sum on study, i ncluding the baseline sum.  In addition to 
the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5  mm. Definitive new lesion presence also indicates progression.  
Stable Disease (SD)  Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as a reference the smallest sum diameters while on study.  
 
NON-TARGET LESIONS  
Lesions Response:  Definition:  
Complete Response (CR)  The disappearance of all non -target lesions. All lymph nodes must be non-
pathological morphologically (ie, < 10 mm in short axis in size).  
Non-CR/Non-PD A persistence of â‰¥ 1 non-target lesion( s)/ not reaching the extent of â€œunequivocal 
progressionâ€.  
Progressive Disease (PD)  Unequivocal progression of existing non -target lesions (see definition below).  
 
Progression in Non- target Disease :  
There must be an overall level of substantial worsening in non- target disease such that, even in 
the presence of SD or PR  in target disease, the overall tumor burden has increased sufficiently to 
merit discontinuation of therapy. 
Because worsening in non -target disease cannot be easily quantified, a useful test that can be 
applied when assessing patients for unequivocal progression is to consider if the increase in 
overall disease burden based on the change in non- measurable disease is comparable in 
magnitude to the increase that would be required to declare PD  for measurable disease; ie, an 
increase in tumor burden representing an additional 73% increase in â€œvolumeâ€ (which is equivalent to a 20% increase in diameter in a measurable lesion).  
[IP_ADDRESS].2. Additional Criteria to Consider When Assessing Tumor Response  
When effusions are known to be a potential adverse effect of treatment, cyt ological confirmation 
of the neoplastic origin of any effusion that appears or worsens during treatment when the measurable tumor has met criteria for response or SD is not mandatory, but might be performed 
to differentiate between response (or SD) and PD when substantial change of effusion and or 
ascites is noted.  
For equivocal findings of progression (eg, very small and uncertain new lesions; cystic changes 
or necrosis in existing lesions), treatment may continue until the next scheduled assessment. If at 
TAS-102 
Protocol No. TO -TAS-102-203 Metastatic Colorectal Cancer  
TO-TAS-102-203 Version 1.0 14 June 2016  Page 62 of 80 the next scheduled assessment, progression is confirmed, the date of progression should be the 
earlier date when progression was suspected.  
[IP_ADDRESS]. RECIST Overall Response Assessment  
Assessments will be made based on definitions14 provided in Table 11.  
Table 11: Time Point Response for Patients with Target (Â± Non -target) Disease  
Target Lesions Non-target Lesions New Lesion  Overall Response  
CR CR No CR 
CR Non-CR/Non-PD or Not 
all evaluated  No PR 
PR Non-PD or Not all 
evaluated  No PR 
SD Non-PD or Not all 
evaluated  No SD 
Not all evaluated  Non-PD No Not evaluable  
PD Any Yes or No  PD 
PD PD Yes or No  PD 
Any Any Yes PD 
Abbreviations: CR = complete response; PD = progressive disease; PR  = partial response; SD = stable disease. 
10.3.3. RECIST Best Overall Response Assessment  
The best overall response as per RECIST criteria is the best response recorded from the start of the study treatment until the end of  treatment.  
11. REPORTING SAFETY INFORMATION 
11.1. Adverse Events and Serious Adverse Events  
11.1.1. Adverse Events  
An AE is any untoward medical condition that occurs in a patient while participating in a clinical 
study and does not necessarily have a causal relationship with  the use of the study drugs. 
Treatment -emergent AEs are AEs that occur from the initiation of any study treatment 
administration, and do not necessarily have a causal relationship to the use of the study 
treatment s.  
Provide a complete and specific clinical dia gnosis as an AE verbatim term. If a diagnosis is not 
available, then report signs and symptoms. The CTCAE terms are to be used to assess severity/provide the grade for each AE that is reported.  
Refer to Section 11.1.5, Section 11.1.6, and Section  11.1.[ADDRESS_18007] medical event that occurs outside the period of patient follow-up ([ADDRESS_18008] dose of study treatment or until the start of new antitumor therapy, whichever is earlier) 
is not considered an AE unless determined by [CONTACT_941] i nvestigator to have a causal relationship with 
the study treatment.  
If any SAEs are observed after the patient follow -up period has ended, only those SAEs 
determined to have a causal relati onship with the study drugs will be recorded in the case report 
form. 
Symptoms or laboratory or instrumental (eg, electrocardiographic) abnormalities of a pre-existing disease, such as cancer or other disease, s hould not be considered an AE. However, 
occurrences of new symptoms as well as worsening of pre- existing medical conditions are 
considered AEs. In addition, a new laboratory or instrumental abnormality that has a clinical impact on a patient (e g, resulting in study drugs dose reduction, treatment delay, treatment 
discontinuation, requires treatment due to abnormal values, or is conside red medically important 
by [CONTACT_093]) is considered an AE, unless it is considered part of clinical manifestations to 
a clinical diagnosis that is already reported as an AE.  
Adverse event s will be reported from the time of informed consent through the period of patient 
follow-up ([ADDRESS_18009] dose of study drugs or until the start of new antitumor therapy, 
whichever is earlier). Document al l AEs in the source documents. Documentation should include 
onset and resolution, severity/grade, relationship to study drugs, and outcome of the event. 
Causal relationship: 
When assessing AE causal relationship  to study drugs, relationship to TAS -102 and nivolum ab 
will be assessed  independently. 
1. Reasonably possible
: The AE is related if it follows a reasonable temporal sequence from 
administration of study drug s and, one of the following conditions is true: 
â€¢ A positive de- challenge. This means that the event resolves when the drug is 
stopped. 
â€¢ A positive re-challenge. This means that the event reappears when the drug is 
restarted. 
â€¢ Or, the event cannot be reasonably explained by [CONTACT_102]â€™s clinical state 
and/or other administered therapi[INVESTIGATOR_014]. 
2. Not reasonably possible : The AE is not related when there is no reasonable possibility 
that the stud y drugs caused the event. For the purposes of safety reporting, â€œno reasonable 
possibilityâ€ means there is no evidence to suggest a causal relationship between the drug 
and the AE. 
Reasonable possibility is provided by [CONTACT_19115] a causal relationship between drug and AE: 
â€¢ A single occurrence of an event that is uncommon and known to be strongly 
associated with drug exposure (eg, angioedema, hepatic injury, Stevens-Johnson 
syndrome) 
TAS-102 
Protocol No. TO -TAS-102-203 Metastatic Colorectal Cancer  
TO-TAS-102-203 Version 1.0 14 June 2016  Page 64 of 80 â€¢ One or more occurrences of an event that is not commonly associated with drug 
exposure, but is otherwise uncommon in the population exposed to drug (eg, 
tendon rupture) 
Outcome:  
â€¢ Resolved without sequelae 
â€¢ Resolved with sequelae 
â€¢ Resolving (can only be used for SAEs and cannot be a final outcome) 
â€¢ Unresolved 
â€¢ Death 
Any unresolved AEs should be followed until the earliest occurrence of one of the following: 
â€¢ AE has resolved. 
â€¢ AE has stabilized. An AE cannot be considered stabilized while the patient is on 
study drug. Ongoing AEs must be assessed for stabilization [ADDRESS_18010] study drug discontinuation. 
â€¢ The start of new antitumor therapy. 
11.1.2. Serious Adverse Events  
An SAE (experience) is any untoward medical occurrence that at any time:  
a. Results in  death (see Section 11.1.3). 
b. Is life threatening.  
NOTE: The term "life threatening" in the definition of "serious" refers to an event in 
which the patient was at risk of death at the time of the event; it does not refer to an 
event which hypothetically might have caused death if it were more severe.  
c. Requires inpatient hospi[INVESTIGATOR_1081]. The 
following are not considered hospi[INVESTIGATOR_19085]:  
âˆ’ Emergency room visits less than 24 hours. 
âˆ’ Hospi[INVESTIGATOR_19086]. 
âˆ’ Hospi[INVESTIGATOR_19087] -related treatment and procedures.  
d. Results in persistent or significant incapacity or disability, where disability is defined as a substantial disruption of a personâ€™s ability to conduct normal life functions, either reported or defined as per clinical judgment. 
e. Is a congenital anomaly/birth defect (if exposure to product just before conception or during pregnancy resulted in an adverse outcome in the child). 
f. Is any other important medical event, eg, may not result in death, be life- threatening, 
or require hospi[INVESTIGATOR_059], but based upon appropriate medical judgment, it may jeopardize the patient and may require medical or surgical intervention to prevent one 
of the outcomes listed in the points above. Examples of such events are: intensive 
TAS-102 
Protocol No. TO -TAS-102-203 Metastatic Colorectal Cancer  
TO-TAS-102-203 Version 1.0 14 June 2016  Page 65 of 80 treatment in an emergency room or at home for allergic bronchospasm; and blood 
dyscrasias or  convulsions that do not result in hospi[INVESTIGATOR_059]. 
Serious adverse events must be reported to Taiho Pharmacovigilance or designee within 
[ADDRESS_18011] becomes aware of the SAE.  Comprehensive 
information available at the time of initial reporting (including narrative description, medical history and concomitant medications) needs to be provided with careful consideration regarding causality and serious criteri a. The SAE reporting process and contact [CONTACT_19116]/SAE Completion Guidelines. 
After the initial SAE notification to Taiho Pharmacovigilance or designee, follow -up SAE 
information will be submitted each time that important follo w-up information (eg, diagnosis, 
outcome, causality assessment, results of specific investigations) becomes available.  
All SAEs within the follow-up window (eg, within [ADDRESS_18012] dose of study drug or 
until the start of new antitumor therapy, w hichever is earlier) established in the protocol will be 
reported to Taiho Pharmacovigilance or designee.  
If serious medical occurrences including deaths outside the follow-up window established by [CONTACT_19117] i nvestigator that he/she believes are related to the 
administration of the inve stigational product, it is the investigatorâ€™s responsibility to report this 
occurrence to Taiho Pharmacovigilance or designee.  
A serious adverse reaction  (SAR) is any event that meets the  definition of an SAE and is 
considered related to the admi nistration of study drugs. An unexpected SAR is defined as any 
SAR, the nature or severity of which is not consistent with the applicable product information 
(eg, IB for an unauthorized investigational product or summary of product characteristi cs for an 
authorized product). 
11.1.3. Reporting of Deaths 
All deaths occurring through the 30-day follow-up period must be reported in the eCRF within  
24 hours. 
1. Death due to disease progression:  
Disease progression (radiologic or clinical) with the outcome of death w ill not be 
reported as an SAE. However, relevant signs, symptoms and complications of disease 
progression (radiologic or clinical) must be reported as an AE or SAE if it meets the 
serious criteria. It should be indicated that the signs, symptoms and complications are 
related to disease progression.  
2. Death due to other causes:  
Deaths due to reasons other than disease progression must be reported as an SAE. 
Death is not an acceptable AE/SAE term. Death is an outcome of an SAE. 
When reporting a death in the eCRF, the investigator will be required to identify which of the 
following best describes the category of death :  
â€¢ Toxicity for study drugs 
â€¢ Radiologic disease progression  
TAS-102 
Protocol No. TO -TAS-102-203 Metastatic Colorectal Cancer  
TO-TAS-102-203 Version 1.0 14 June 2016  Page 66 of 80 â€¢ Clinical disease progression  
â€¢ Other causes  
11.1.4. Disease Progression  
1. How to report events related to non- fatal disease progression:  
a. Disease progression  is not an acceptable AE term. In cases of non -fatal disease 
progression, the relevant signs, symptoms and complications should be reported as an 
AE unless they meet the serious criteria. If any of the signs, symptoms and 
complications meets any of the serious criteria, they should be reported as an SAE. In 
both cases it should be indicated whether the signs, symptoms and complications are related to disease progression.  
b. Radiologic disease progression without relevant signs, symptoms and complications will not be reported as an AE or SAE. 
2. How to report events related to fatal disease progression:  
a. See Section 11.1.3, Reporting of Deaths. 
11.1.5. Pregnancy  
If a patient becomes pregnant while in the study, the study treatment mus t be immediately 
discontinued. Pregnancy information for a female patient should be reported within [ADDRESS_18013] becomes aware of a pregnancy or its outcome. This should be 
performed by [CONTACT_12550] a Pregnancy Form and faxing it to Taiho Pharmacovigilance or 
designee. 
New and/or corrected information regarding the pregnancy obtained after submitting the initial 
Pregnancy Form must be submitted by [CONTACT_19118].  
If outcome of the pregnancy is a stillbirth, congenital anomaly/birth defect, or a serious event in 
the mother, report as an SAE to Taiho Pharmacovigilance or designee. 
11.1.6. Medication Errors  
A medication error is defined as any accidental incorrect adminis tration of a medicinal product. 
The error may be related to the administration of a wrong medication, nature of the medication, 
route of administration, dosage or frequency of the treatment as specified in this protocol 
(including omission of one or more administrations). 
â€¢ Medication errors wi th study drugs and concomitant medication treatment will 
not be recorded in the eCRF unless they result in an AE. 
â€¢ Medication errors with study drugs that result in an overdose will be captured as 
an AE in the eCRF.  
â€¢ Medication errors with study drugs that do not result in an AE should be 
handled as follows: 
âˆ’ If it results in the omission of an administration, an incorrect dose (relative to that specified in this protocol), or the administration of more than the 
TAS-102 
Protocol No. TO -TAS-102-203 Metastatic Colorectal Cancer  
TO-TAS-102-203 Version 1.0 14 June 2016  Page 67 of 80 prescribed dose (but does not meet the overdose criteria), it will be 
identified through the recording of study drug accountability data in the 
eCRF and does not need to be reported as an AE. 
âˆ’ If it results in an overdose, incorrect route of administration, or administration of an incorrect study drug, it will be reported as an AE.  
Based on the above criteria, medication errors that are captured as an AE on the eCRF should be 
reported to Taiho Pharmacovigilance or designee within [ADDRESS_18014] becomes aware of its occurrence following the same process as described for the SAEs even if it does not meet any of the criteria of an SAE.  
11.1.7. Overdose  
An overdose with TAS- 102 for this clinical trial is defined as:  
â€¢ Taking a dose beyond the recommended dose in 1 day or beyond the recommended total dose in each cycle.  
An accidental or intentional overdose with TAS- 102 regardless of whether it is associated with 
an AE (even if not fulfilling a seriousness criterion) is to be captured as an AE on the eCRF and reported to Taiho Pharmacovigil ance or designee within [ADDRESS_18015] potential side effects.  
Overdose with nivolumab is defined as administering quantities above the 
recommended/schedule dosage per the nivolumab la bel, large enough to overwhelm the 
homeostasis, disrupting wellbeing, or causing severe illness and/or death. Any overdose with nivolumab associated with AEs should be reported to Taiho Pharmacovigilance or designee within [ADDRESS_18016] be reported as an AE, unless it is 
considered a supporting laboratory result to a clinical diagnosis that is already reported as an AE. 
TAS-102 
Protocol No. TO -TAS-102-203 Metastatic Colorectal Cancer  
TO-TAS-102-203 Version 1.0 14 June 2016  Page 68 of 80 If there is a questi on or concern, please call the Sponsorâ€™s medical monitor. All laboratory data 
will be analyzed using NCI CTCAE grade criteria.  
11.2.2. Repeat Testing  
Repeat the evaluation of any clinically significant laboratory test, as clinically indicated, until the 
value returns to the baseline level or clinically stabilizes, or until another treatment is given.  
11.3. Physical Examination and Performance Status  
Perform physical examinations and performance status evaluations as described in the s tudy 
procedures section of the protocol. If changes are observed, determine whether they meet the 
definition of an AE. All observations and evaluations should be documented. 
11.4. Vital Sign Measurements and Body Weight  
Verify and document vital sign measurements and body weight. If a clinically significant change 
is observed, repeat the measurement as clinically indicated and evaluate for its clinical relevance 
and whether it meets the definition of an AE. 
12. STATISTICS  
A Statistical Analysis Plan (SAP) that includes a more technical and detailed descri ption 
(including templates for tables, listings, and f igures) of the planned statistical summaries 
analyses will be prepared.  
12.1. Study Populations  
The study populations for all analyses are defined as: 
â€¢ Safety Population: Includes all patients w ho received at least 1 dose of study drug. It 
will be the primary population for safety analyses. 
â€¢ DLT Evaluable Population: Included all patients in the safety population in Stage 1, prior to confirming the recommended dose, who completed at least 1 cycle (28 days) 
of study treatment with at least 80% of the study treatment administered, unless the treatment was interrupted because of a DLT.  
â€¢ Efficacy Population: Includes all patients in the safety population who completed at 
least 6 months of tumor follow-up (evaluable irRC and/or RECIST assessments), 
unless the patient progressed or died before the 6-month follow-up. 
12.2. Study Endpoints  
12.2.1. Primary Efficacy Endpoint 
The primary efficacy endpoint is irORR  which is defined as the incidence of complete  (irCR) 
and partial (irPR) responses in the efficacy population.  
7$6
3URWRFRO1R727$6 0HWDVWDWLF&RORUHFWDO&DQFHU
727$69HUVLRQ-XQH  3DJH RI6HFRQGDU\(QGSRLQWV
6HFRQGDU\HIILFDF\HQGSRLQWVLQFOXGH
x'/7VRIWKHFRPELQDWLRQWKHUDS\
x,QFLGHQFHRI$(VDQGODE RUDWRU\WHVWDEQRUPDOLWLHV
x5(&,67255GHILQHGDVWKHLQFLGH QFHRIFRPSOHWH5(&,67&5DQG SDUWLDO
5(&,6735UHVSRQVHVLQWKHHIILFDF\SRSXODWLRQ
x3)6GHILQHGDVWKHWLPHIURPWKH ILUVWGRVHRIVWXG\GUXJWRGL VHDVHSURJUHVVLRQEDVHG
RQLU5&DQG5(&,67LQWKHHIILFDF\SRSXODWLRQ
x'&5GHILQHGDVWKHLQFLGHQFHRI QR3'SDWLHQWVEDVHGRQWKHLU 5&DQG5(&,67LQ
WKHHIILFDF\SRSXODWLRQ
x26GHILQHGDVWKHWLPHIURPWKHIL UVWGRVHWRGHDWKLQWKHVDIH W\SRSXODWLRQ3DWLHQWV
DOLYHDWWKHWLPHRIVWXG\GLVF RQWLQXDWLRQZLOOEHFHQVRUHG$G GLWLRQDOFHQVRULQJUXOHV
ZLOOEHGHILQHGLQWKH6$3
$QDO\WLFDO0HWKRGV
3DWLHQW'LVSRVLWLRQ%DVHOLQHDQG7UHDWPHQW&KDUDFWHULVWLFV
3DWLHQW'LVSRVLWLRQ
7KHQXPEHURISDWLHQWVLQ HDFKVWXG\SRSXODWLRQDQGWKHUHDVRQV IRUH[FOXVLRQZLOOEH
VX[COMPANY_003]UL]HG,QDGGLWLRQSDWLHQWV WKDWGLVFRQWLQXHVWXG\WUHDWP HQWRUVWXG\IROORZXSZLOODOVREH
VX[COMPANY_003]UL]HGDORQJZLWKUHDVRQV IRUVWXG\GLVFRQWLQXDWLRQ
3DWLHQW%DVHOLQH&KDUDFWHULVWLFV
3DWLHQWGHPRJUDSKLFDQGGLVHDVHFKDUDFWHULVWLFVDW%DVHOLQHZLO OEHVX[COMPANY_003]UL]HGLQIUHTXHQF\
WDEOHVRUZLWKVX[COMPANY_003]U\VWDWLVWLF VIRUFRQWLQXRXVYDULDEOHV
6WXG\7UHDWPHQW
6WXG\GUXJDGPLQLVWUDWLRQSURILOH VZLOOEHVX[COMPANY_003] UL]HGGHVFULSWL YHO\IRU7$6DQGQLYROXPDE
ZLWKUHVSHFWWRQXPEHURIF\FOHV WDNHQWKHFXPXO DWLYHGRVHWK HGRVHLQWHQVLW\WKHUHODWLYHGRVH
LQWHQVLW\DQGGRVHPRGLILFDWLRQV
1RQ6WXG\7UHDWPHQWLQWKH6WXG\)ROORZXS3HULRG
7KHQXPEHUW\SHDQGH[WHQWRI XVHRIQRQVWXG\FDQFHUWUHDWPH QWVDIWHUVWXG\WUHDWPHQW
GLVFRQWLQXDWLRQZLOOEHV X[COMPANY_003]UL]HG$Q\XVHRIQRQVWXG\FDQFHU WUHDWPHQWVGXULQJWKHVWXG\
WUHDWPHQWSHULRGZLOODOVREHSUHVHQWHGCCI
TAS-102 
Protocol No. TO -TAS-102-203 Metastatic Colorectal Cancer  
TO-TAS-102-203 Version 1.0 14 June 2016  Page 70 of 80 12.3.2. Efficacy Analysis 
Descriptive statistics such as incidence of responses (ORR and DCR) for eac h set of criteria, and 
associated 95% confidence intervals ( CIs) will be provided.  
For the time to event endpoints, PFS (both sets of tumor response criteria), the Kaplan- Meier 
estimates will be derived and the associated 95% CIs will be provided. 
12.3.3. Safety Analyses 
The safety evaluations will focus on AEs and laboratory assessments. All patients included in the 
ITT Population will be evaluated in the safety analysis. 
Adverse events will be coded according to the Medical Dictionary for Regulatory Activities 
(MedDRA)  terminology and the severity of the toxicities will be graded according to the NCI 
CTCAE cri teria, where applicable.  Concomitant medications will be coded according to the 
World Health Organization Drug Dictionary. Hematological and chemistry labo ratory 
parameters will be graded according to the NCI CTCAE criteria, where applicable.  
All AEs will be summarized (incidence) and listed by [CONTACT_19119], preferred term, toxicity/severity grade, and causal relationship to study drugs. In addition, separate summaries of 
the DLTs, at each dose level as applicable, SAEs, and grade [ADDRESS_18017] severity grade, and time to event will also be summarized.  
12.4. Justification of Sample Size  
Sample size considerations are based on a 2- stage minimax Simonâ€™s design, testing a null 
hypothesis (poor response) of 10% or less immune -related overall response ( irOR) versus an 
alternative hypothesis (promising response) of 30% or greater irOR at an approximate 5% 1-
sided significance level and 80% power. In Stage 1 (futility assessment), enrollment will include 
[ADDRESS_18018] 2 of 15 
(13%) patients respond (PR or CR). The probability of early stoppi[INVESTIGATOR_19088] 55%. In Stage 2, if the Stage [ADDRESS_18019] 6 of 25 (24%) patients respond. 
If the initial dose is not tolerated in the first 6 patients in Stage 1, an additional 6 DLT -evaluable 
patients will be enrolled at the reduced dose. Assuming a 10-15% non- evaluability  for DLT 
and/or irRC assessment rate, a total of 30 to 35 patients is  expected to be enrolled in the study. 
12.5. Interim Analyses  
An interim analysis for efficacy and futility is planned for the study after Stage 1 enrollment is 
completed. At the point that the ninth patient is enrolled  (or a total of at least 15 patients 
evaluable for response assessment at the target  dose), enrollment will stop, and there will be an 
assessment of safety and efficacy to determine whether the second stage of an additional 10 
patients evaluable for response will be enrolled. 
TAS-102 
Protocol No. TO -TAS-102-203 Metastatic Colorectal Cancer  
TO-TAS-102-203 Version 1.0 14 June 2016  Page 71 of 80 13. ETHICS 
13.1. Ethical Considerations  
It is mandatory that all considerations regarding t he protection of human subjects be carried out 
in accordance with the protocol, Good Clinical Practice (GCP),  ICH Guidelines, the ethical 
principles that have their origin in the Declaration of Helsinki, and all applicable regulatory 
requirements.  
13.2. Informed  Consent and Patient Information  
Obtaining informed consent must be done according to the guidelines provided in the 
Declaration of Helsinki, ICH E6 Guideline for GCP, and local regulations. 
The investigator (according to applicable regulatory requirements) or a person designated by [CONTACT_19120] i nvestigatorâ€™s responsibility should fully inform patients of all 
pertinent aspects of the clinical trial. All participants should be informed to the fullest extent 
possible about the study in a language and in terms they are able to understand. 
Before participation in the trial, the written ICF is to be signed and personally dated by [CONTACT_19121]â€™s legal representative and by [CONTACT_19122]. A copy of t he signed and dated ICF will be provided to the patient. The ICF used 
must have had prior approval by [CONTACT_1201]/Independent Ethics Committee (IEC). 
13.3. Institutional Review Board/Independent Ethics Committee Approval  
The study must be approved by [CONTACT_19123]/IEC, as required in Chapter 3 of 
the ICH E6 Guidelines.  
The IRB/IEC must provide written approval of the study. The written approval/favorable opi[INVESTIGATOR_19089] (title, number and version number), list of documents reviewed (eg, 
protocol, ICF, IB, curriculum vitae), and the date of the review.  
The investigator is required to submit a copy of the written and dated IRB/IEC 
approval/favorable opi[INVESTIGATOR_19090]. 
Investigational product will not be rele ased to the trial site and the i nvestigator will not start the 
trial until this written IRB/IEC approval/favora ble opi[INVESTIGATOR_19091].  
The investigator is responsible for obtaining renewal of approval throughout the duration of the 
study. Timeframes for renewal will be based on IRB/IEC requirements , but renewal at least 
annually is required by [CONTACT_19124]. 
At the end of the trial, the IRB/IEC will be notified of the conclusion of the trial and its outcome. 
TAS-102 
Protocol No. TO -TAS-102-203 Metastatic Colorectal Cancer  
TO-TAS-102-203 Version 1.0 14 June 2016  Page 72 of 80 14. ADMINISTRATIVE CONSI DERATIONS  
14.1. Protocol Amendments 
No change to the protocol may be made without the agreement of Taiho Oncology, Inc. Any 
amendment to the original protocol will be made by [CONTACT_19125], Inc. and will be submitted to the IRB/IEC and appropriate regulatory authorities for approval or notification. 
14.2. Curriculum Vitae  
All investigators and any sub-investigator(s) must provide Taiho Oncology, Inc. with current (within 2 years) signed and dated copi[INVESTIGATOR_19092], qualifications, and training before the beginning of the study. 
14.3. Administrative Structure  
The administrative structure of the study (eg, Contract Research Organizations) will be provided 
to all sites.  
14.4. Monitoring Procedures  
14.4.1. Investigatorâ€™s Responsibilities  
The investigator agrees to conduct the study in accordance with the Clinical Trial Protocol, ICH 
guidelines E6 â€“ GCP, Section 4 â€“ Investigatorâ€™s obligations and the applicable regulatory requirements.  
The investigator is required to ensure compliance with the protocol and other procedures 
provided by [CONTACT_1034]. The i nvestigator agrees to provide reliable data and all information 
required by [CONTACT_760], eCRF, SAE forms, and Data Resolution Forms or any other appropriate 
instrument. This information must be accurate, legible and according to instructions provided. 
The investigator  must ensure that the Sponsor, Sponsorâ€™s representatives and regulatory agencies 
will have access to such documentation. 
The investigator may appoint sub- investigators  to assist in the conduct of the trial. All 
sub-investigators shall be appointed and listed in a timely manner. They will be supervised and 
work under the responsibility of the investigator. 
14.4.2. Sponsorâ€™s Responsibilities  
The Sponsor is respons ible to health authorities for taking all reasonable steps to ensure the 
proper conduct of the clinical trial protocol with regard to ethics, protocol compliance, and 
integrity and validity of t he data recorded in the eCRFs. Thus, the main duty of the stud y site 
monitor (Clinical Research Associate ) is to help the investigator and the Sponsor maintain a high 
level of ethical, scientific, technical, regulatory, and quality in all aspects of the trial.  
At regular intervals during the trial, the site will be c ontacted, through monitoring visits, letters 
or telephone calls by [CONTACT_19126], investigator and 
patientâ€™s compliance with requirements, and follow up on any issues to be addressed. During the 
TAS-[ADDRESS_18020] the source 
documents. Source documents are original documents, data, and records (eg, hospi[INVESTIGATOR_1097], clinical and office charts, laboratory notes, memoranda, subjectâ€™s evaluation checklists, 
pharmacy dispensing records, recorded data from automated instruments, copi[INVESTIGATOR_19093], microfiches, photographic negatives, 
microfilm or magnetic media, X -rays, subject files, and records kept at the pharmacy, at 
laboratories, and at medical -technical departments involved in the clinical trial).  
The informed consent will include a statement by [CONTACT_19127]â€™s duly authorized personnel, the IRB/IEC, and regulatory authorities to have direct access to original 
records supporting eCRF data. 
The use of pencil and correction fluids is not accepted for recording clinical research 
information. Corrections in source documents must be done by [CONTACT_19128] a single line, 
then initialing and dating and recording the corrected information. 
14.4.4. Case Report Form  
Electronic case report form s will be provided by [CONTACT_1034]. 
Investigators will be provided with detailed eCRF Completion Guidelines that will identify the 
required data points to be collected, how to document them, and when the data should be documented. 
It is the responsibility of the investigator to maintain adequate and accurate eCRFs to record 
(according to the eCRF Completion Guidelines) all observations and other data pertinent to the clinical trial obtained during sc heduled or unscheduled visits. All eCRFs should be fully 
completed to ensure accurate data interpretation.  
The computerized handling of the data by [CONTACT_19129] i nvestigator is 
obliged to respond by [CONTACT_19130]. These requests with their responses will be included in the eCRFs held by [CONTACT_8981]. 
14.4.5. Sponsorâ€™s Audits and Regulatory Inspections  
For the purpose of ensuring compliance with the protocol, GCP and applicabl e regulatory 
requirements, the investigator will permit auditing by [CONTACT_19131]. 
The investigator agrees to allow the auditors and inspectors to have direct access to the study 
records for review. The people performing these activities will not disclose any personal identity 
or personal medical information assessed. 
The investigator will make every effort to help with the performance of the audits and 
inspections, giving access to all necessary facilities, data and documents per taining to the clinical 
TAS-102 
Protocol No. TO -TAS-102-203 Metastatic Colorectal Cancer  
TO-TAS-102-203 Version 1.0 14 June 2016 Page 74 of 80 trial. As soon as the investigator is notified of a planned inspection by [CONTACT_19132]/IEC, the investigator will inform the Sponsor. Any results arising from such inspections 
will be immediately communicated by [CONTACT_3433] e investigator to the Sponsor. The i nvestigator shall take 
appropriate measures required by [CONTACT_19133]. 
14.5. Archiving of Records 
The investigator is responsible for the retention of all study documents according to institutional 
policies, local laws, ICH guidelines E6 â€“ GCP, Sections 4.9.4 and 4.9.5 and, for studie s 
conducted under an Investigationa l New Drug application, the US Code of Fede ral Regulations 
Title 21 part 312.62. For more information on [LOCATION_003] requirements and ICH Guidelines, please 
go to http://www.fda.gov a nd http://www.ema.europa.eu. 
The investigator agrees to inform the Sponsor in writing of the intention to remove or destroy 
any study-related records. Before cont acting the Sponsor, the i nvestigator must ensure that 
institutional and local requirements (for example, ICH Gu idelines) have been satisfied. The 
Sponsor will evaluate the investigatorâ€™s request and provide authorization for destruction of such 
records to the i nvestigator in writing.  
In the event that all retention of records requirements have been fulfilled, but the Sponsor 
requests that the i nvestigator maintain the records for a longer period of time, additional 
arrangements will be made.  
14.6. Final Report  
Whether the study is completed or prematurely terminated, a final report of the study will be 
written by [CONTACT_19134](ies), as required by [CONTACT_1729].  
The final study report will be retain ed by [CONTACT_19135], for [ADDRESS_18021]. 
14.7. Use and Publication of Study Results  
The investigator agrees that the Sponsor maintains the right to use the results of this study in 
their original form and/or in a global report for submission to governmental and regulatory 
authorities of any country. Data from this study must not be published without prior 
authorization from the Sponsor. 
The results of the study may be presented during scienti fic symposia or published in a scientific 
journal only after review by [CONTACT_19136]. 
14.8. Financial Disclosure  
Financial disclosure for clinical investigators will b e obtained and record keepi[INVESTIGATOR_19094] s Title 21 part 54. 
TAS-102 
Protocol No. TO -TAS-102-203 Metastatic Colorectal Cancer  
TO-TAS-102-203 Version 1.0 14 June 2016  Page 75 of 80 14.9. Termination of the Study  
If the Sponsor and/or the investigator should discover conditions aris ing during the study that 
indicate it should be terminated, an appropriate schedule for t ermination will be instituted. The 
Sponsor also reserves the right to discontinue this study for administrative reasons at any time. 
15. CONFIDENTIALITY AND DATA PROTECTION 
All information provided to the investigator by [CONTACT_13679]â€™s representatives, 
information produced during the clinical trial including, but not limited to the protocol, eCRF, IB, and the results obtained during the course of the trial is conf idential. The members of the 
research team agree not to discuss such information in any way without prior written permission from the Sponsor. 
However, the submission of the protocol and necessary documentation to the IRB/IEC is 
permitted. The IRB/IEC memb ers have the same obligation of confidentiality.  
The patientâ€™s personal data and investigatorâ€™s personal data that may be included in the 
Sponsorâ€™s database shall be treated in compliance with all applicable laws and regulations. 
When processing and archiving p ersonal data pertaining to the investigator and or to the patients, 
the Sponsor or its representatives shall take all appropriate measures to safeguard and prevent 
access to this data by [CONTACT_13159]. 
[COMPANY_003][COMPANY_003]PP
D
TAS-[ADDRESS_18022] OF REFERENCES
1.Heidelberger C, Parsons DG, Remy DC. Syntheses of 5- trifluoromethyluracil and 5 -
trifluoromethyl- 2â€™-deoxyuridine. J Med Chem . 1964;7:1-5.
2.Gottschling H, Heidelberger C. Fluorinated pyrimidines. XIX. Some biologic al effects of
5-trifluoromethyluracil and 5 -trifluoromethyl -2â€™-deoxyuridine on escherichia coli  and
bacteriophage T4B. J Mol Biol. 1963;7:541-60.
3.Reyes P, Heidelberger C. Fluorinated pyrimidines. XXVI. Mammalian thymidylate
synthetase: its mechanism of act ion and inhibition by [CONTACT_19137]. Mol
Pharmacol . 1965;1:14-30.
4.Heidelberger C,  Anderson SW. Fluorinated pyrimidines. XXI. The tumor-inhibitory
activity of 5 -trifluoromethyl-2â€™-deoxyuridine. Cancer Res . 1964;24:1979-85.
5.Heidelberger C, Boohar L , Kampschroer B. Fluorinated pyrimidines. XXIV. In vivo
metabolism of 5 -trifluoromethyluracil-2-C14 and 5- trifluoromethyl -2â€™-deoxyuridine-2-
C14. Cancer Res . 1965;25:377-81.
6.Santi DV, Sakai TT. Thymidylate synthetase. M odel studies of inhibition by
5-trifluoromethy-2â€™- deoxyuridylic acid. Biochemistry . 1971;10:3598-3607.
7. Fukushima M, Suzuki N, Emura T, Yano S, Kazuno H, Tada Y, et al. Structure and
activity of specific inhibitors of thymidine phosphorylase to potentiate the function of
antitumor  2â€™-deoxyribonucleosides. Biochem Pharmacol . 2000;59:1227-1236.
8.Mayer RJ, Van Cutsem, Falcone A, et al. Randomized trial of TAS-102 for refractory
metastatic colorectal cancer. N Engl J Med . 2015;372:1909-19.
9.American Cancer Society. Cancer Facts & Figures 2016. Atlanta: American Cancer
Society; 2016.
10.Le DT, Uram JN, Wang H, et al. PD -1 blockade in tumors with mismatch -repair
deficiency. N Engl J Med . 2015;372(26):  2509-20.
11. Benson AB 3rd, Ajani JA, Catalano RB, Engelking C, Kornblau SM, Martenson JA Jr, et
al. Recommended guidelines for the treatment of canc er treatment -induced diarrhea. J
Clin Oncol . 2004;22(14):2918-26.
12. American Society of Clinical Oncology, Kris MG, Hesketh PJ, Somerfield MR, Feyer P,
Clark-Snow R, et al. American Society of Clinical Oncol ogy guidelines for antiemetics in
oncology: update 2006. J Clin Oncol. 2006;24:2932-47.
13. Wolchok JD, Hoos A, Oâ€™Day S, et al. Guidelines for the evaluation of immune therapy
activity in solid tumors: immune -related response criteria. Clin Cancer Res .
2009;15(23):7412-20. Epub [ADDRESS_18023] R, et al. New
response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1).
Eur J Cancer . 2009;45:228-47.